No bio available.

• Data Platforms & Storage Infrastructure

At Novo Nordisk, Rahmad enables patients to realize their greatest potential by catalysing antibody design. He leverages experimental data, molecular simulation, and artificial intelligence to build computational oracles and to design antibody therapeutics faster, smarter, and cheaper.

• W6: AI in Antibody Design

No bio available.

• Data Science & Analytics Technologies

Prof. Saeed Amal is a Research Professor at the department of bioengineering at Northeastern University. Amal is a member of The Roux Institute and The Institute for Experiential AI. Amal was a Postdoctoral Fellow at the Stanford University School of Medicine where he focused on the applications of artificial intelligence to improve healthcare, specifically care for cardiovascular disease. He received his PhD and MSc degree in Computer Science from the University of Haifa and a BSc degree in Computer Science from Technion. Amal has vast leadership experience in applied research from the tech industry and is a former VP of an R&D data medical startup in the field of cardiology. His research interests are the healthcare applications for artificial intelligence, including deep learning and machine learning, natural language processing (NLP), image processing, and recommender systems.

• AI for Oncology, Precision Medicine & Health

Rachana Ananthakrishnan is Executive Director & Head of Products at the University of Chicago, and has a Joint Staff Appointment at Argonne National Laboratory. In her role at the university, she leads the Globus (www.globus.org) department, which delivers a research IT platform to national and international research institutions. She currently serves on the Internet2 InCommon Steering Committee, Earth System Grid Federation Executive Committee and Scientific Advisory Board for National Microbiome Data Collaborative. Her work is focused on cyberinfrastructure for enabling research across a variety of domains, and she has led security and data management for several NSF, DOE, and NIH funded initiatives. Rachana was a member of the Globus Toolkit engineering team and customer engagement teams, leading the efforts in web services and security technologies. Rachana received her MS in Computer Science at Indiana University, Bloomington.

• Generative AI Tools

Experienced Community and Data Manager, leading significant data management initiatives for ELIXIR and serving on the management and steering committees of the ELIXIR-UK node. As a leading editor of RDMkit, the ELIXIR data management toolkit for best practices in life sciences, I’m actively involved with the content creation process and editorial responsibilities, ensuring high-quality of data management content. Co-lead of the ELIXIR Research Data Management (RDM) community, fostering and facilitating the usage of the data management resources to promote the application of FAIR principles. Community lead on the ELIXR Training eSupport System (TeSS), a training platform developed to provide a one-stop shop for trainers and trainees to discover online content. In addition, I’m responsible for the product management and community development of the data management platform, FAIRDOM-SEEK, handling its major users spread across the world. With a Ph.D. in bioinformatics from Japan and extensive experience working in different countries and cultures, I engage with a wide range of stakeholders in the field of life sciences.

• W1: FAIRification Lab—Applying FAIR Principles to Enhance Data Stewardship

With a passion for both Life Sciences R&D, Data, and Digital Technologies, John Apathy has devoted his career to helping pharmaceutical R&D organizations to build and sustain mission of discovering and developing new medicines for patients in need. In May 2023, John helped to found XponentL Data, the fastest-growing data, tech, and AI consulting services firm in Health and Life Sciences. XponentL Data is a proud small company member of the Pistoia Alliance. With XponentL, John continues his life’s passion of unlocking value from data and digital technologies to impact patient’s lives through the discovery and development of new therapeutic products. Prior to founding XponentL, John was previously the global Head of Digital/IT for Research and Early Development (R&ED) at Bristol Myers Squibb. His role there was focused on driving new digital capabilities for a broad set of R&ED functions that ranged from basic research of human disease through to proving new medicinal candidates in the patients that BMS strives to serve. With over 35 years of experience in pharmaceutical industry, John is a transformational leader and drove next generation programs at BMS in genetically defined precision medicine, research computing, translational research and development, machine learning, research data integration, and digitally enhancing lab-based researchers. John has both deep knowledge and broad experience gained through his wide range of leadership positions across both the Pharmaceutical and Management Consulting industries at Bristol Myers Squibb, Celgene, GlaxoSmithKline, Wyeth, Accenture, PA Consulting Group, and Eli Lilly and Company. The focus of his efforts though out his career has always been to work collaboratively with colleagues at the boundaries of science, digital technology, and business to deliver high-value results and capabilities for clients and to ultimately benefit patients’ lives. John lives in Devon, PA with his wife in an empty nest as his three adult children have all moved on to pursue their own successful life journeys. When not working for the benefit of clients, you most likely will find John on a golf course.

• Knowledge Graphs

Jared Auclair serves as the Interim Dean of the College of Professional Studies. Appointed in December 2023, Jared leads all academic and administrative functions of the college. With more than a decade of experience at Northeastern, starting first as a post-doc and most recently, Vice Provost Research Economic Development and Director of Bioinnovation, Jared is a champion of innovation and collaboration and deeply values the promise that the College of Professional Studies brings to students as one of Northeastern’s most diverse and dynamic colleges committed to meet students where they are. Prior to his role as Vice Provost Research Economic Development, Jared served as the Associate Dean of Professional Programs and Graduate Affairs in the College of Science, and still holds a faculty appointment in the Department of Chemistry and Chemical Biology. His past experience with the College of Professional Studies includes leadership on a variety of economic and workforce development and research programs, including PlusOne, a dynamic program that gives students the opportunity to accelerate their education by earning both a bachelor’s and master’s degree in five years. With an extensive leadership background, Jared’s passion for progress drives essential strategic initiatives for the College of Professional Studies. His focus on strengthening the connections between education, research, and community, along with fostering a global mindset is core to the College of Professional Studies’ commitment to delivering a world-class experiential education tailored to students’ needs. Prior to joining Northeastern, Jared held a variety of research and consulting roles for leading biopharmaceutical firms. He holds a bachelor’s degree in biotechnology from Worcester Polytechnic Institute and a PhD in Biomedical Science from the University of Massachusetts Medical.

• Data Science & Analytics Technologies

Sophie is the R&D IT Business Partner to the Pharmaceutical Sciences and Biologics Pharmaceutical Development spanning AstraZeneca’s Global CMC network in R&D. She is a member of the Early Science IT Leadership Team and co-chair of AZ Pride Ireland and UK. Sophie joined AstraZeneca in 2005 and has held a number of leading roles across chemical development and product development, delivering drug projects from Phase 1 to commercial submission. In 2019 Sophie led a global digital transformation program, delivering a new digital backbone for data capture, use, and reuse for 1250 scientists across 9 development sites. Her cross disciplinary team has deployed a number of digital solutions, integrating key software and equipment to deliver a seamless data transfer, increasing data quality, and reducing time required for data handling. Sophie has successfully developed business cases to identify critical software and capability build required to increase predictions, advanced modelling, and data science capabilities, allowing scientists to innovate in a simulated environment thereby targeting physical experiments and reducing laboratory waste. Sophie has a PhD in Separation Science with research focused on modelling separation mechanisms of complex polar molecules, she is a Chartered Chemist with Royal Society of Chemistry. Sophie has a diploma in Business Management and is a Chartered Manager with CMI. Sophie is a co-chair of the AZ Pride Ireland and UK group and is passionate about driving equality both inside and outside work. She lives in central Manchester with her miniature dachshund called Data, who is the most important asset in her world.

• Data Management

No bio available.

• Digitalization of Clinical Development

Simon is Head of US Operations and leads US Business Development at PrecisionLife. He has spent more than 25 years in product and business strategy for AI/genomics in healthcare and life science. Previously, Simon was Director of Healthcare at IQVIA, leading their healthcare NLP business for seven years.

• AI for Drug Discovery & Development

Leading Biopharma Human Capital Dynamics research at University of Dundee.

• Data Science & Analytics Technologies

Bridget Behringer brings more than 30 years of diverse biopharmaceutical industry experience in roles of increasing management and strategic leadership within AstraZeneca. She has a strong strategic partnering and technology background and is passionate about applying disruptive technologies and leading business transformations in areas such as biopharmaceutical R&D all the way through to Commercial. She enjoys partnering with senior leaders to define objectives, value, and plan for change. Prior to her current role, Bridget provided IT leadership for the Oncology Digital Health unit in support of their innovative portfolio and external partnering approaches.

• AI for Drug Discovery & Development

WORK EXPERIENCE 2023—Senior Director, Digital Science & Innovation, Novo Nordisk 2021-2023 CEO for DigitalLead, Denmark’s National Cluster for Digital Technologies 2017-2020 CEO for Ørestad Innovation City Copenhagen (ØICC) 2013-2017 Executive director and owner of Office for Leadership Education 2010-2013 Leader of Center for Science Education Studies at University of Copenhagen 2009-2010 Post.doc, at Department of Social Science & Business, RUC FORMAL EDUCATION 2020 – HD in Leadership & Organization, Copenhagen Business School 2005-2009 PhD in Technology and Learning at University of Aarhus (herein a 6 month researcher stay at Deakin University, Melbourne 1998-2000 Master in Multimedia at University of Aarhus 1995-1998 Bachelor in Media Science at University of Aarhus (herein a 6 month study stay at Amsterdam University DUTIES ON BOARD OF DIRECTORS, ADVISORY BOARDS AND COUNSILS 2024 – Board Member Denmark’s Technical Museum 2019 – Chairman at Ørestad Gymnasium 2021-2023 Member of Danish Government Advisory Group for the Danish Defense Industry 2021-2023 Member of Danish Intelligence Service (PET) Business Council 2021-2023 Ambassador for the new Danish Technical Museum at Svanemølleværket 2021-2023 Member of Advisory Board for Digital Hub Denmark 2021-2022 Board Member, Hub for Cybersecurity 2005-2009 Member of the PhD Study Board at University of Aarhus.

• Data Science & Analytics Technologies
• Software Applications & Services

Ari received his Ph.D. in Molecular Biology with a focus on Neuroscience in 2005 from the University of Texas at Austin (UT). His graduate work focused on studying the effects of genetics on addictive behaviors such as alcoholism. His postdoctoral fellowships at the University of California, San Francisco (UCSF) and the Buck Institute for Research on Aging focused on improving our understanding of neurodegenerative diseases of aging (specifically, Parkinson’s and Alzheimers Disease) by utilizing a combination of laboratory science and animal models, as well as bioinformatics and computational biology. Ari is also an expert in Scientific Computing specializing in high performance computing (HPC), high-performance networks, data centers, storage, cloud, general IT infrastructure, and bioinformatics and data analytics. He has been designing, building, and operating scientific computing environments for 27 years and strives to advocate for science and empower researchers to make discoveries from their complex datasets. His ultimate goal is to help create a dynamic enough abstraction of flexible infrastructure from research end-users to enable anyone to analyze and gain knowledge from very complex datasets.

• Cloud for AI/ML & Modern Data Science
• Data Science & Analytics Technologies
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management

J. Rodney Brister, Ph.D., is the Chief of NCBI Viral Resources and the Initiative Owner of the NCBI Cloud Data and Tools (STRIDES) Program. Rodney received his Ph.D. in Molecular Genetics and Microbiology from the University of Florida where he defined the mechanism of Adeno-associated virus genome replication. He went on to describe the orchestration of bacteriophage T4 replication through multiple, genetically discrete origins of replication during post-doctoral work at NIDDK, NIH. Since joining NCBI, Rodney has been involved in several initiatives that support viral surveillance, identification, and accessibility of viral and NGS sequence data via NCBI’s web resources such as NCBI Virus as well as laying the foundation of a cloud dataverse to accelerate biomedical discoveries.

• Cloud for AI/ML & Modern Data Science
• Data Science & Analytics Technologies
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management

No bio available.

• Software Applications & Services

Ben Busby works to make biomedical data science a more productive environment to work in for bioinformaticians and biomedical data scientists. At DNAnexus he does this by prototyping both scientific data integration as well as complex compute environments for users of the UKBioBank, as well as many other folks throughout academia, industry and government. Ben also develops prototype software in machine learning, omics, imaging, pharmacogenomics and NLP with his group, as well as in a number of hackathons he runs and participates in around the world. Prior to DNAnexus, Ben consulted for Johns Hopkins University, Ariel Precision Medicine, Deloitte, and NCBI, as well as founding the Bioinformatics and Data Science department at the FAES Graduate School on the NIH campus.

• Knowledge Graphs
• Generative AI Tools
• Pharmaceutical R&D Informatics

KATY BÖRNER is the Victor H. Yngve Distinguished Professor of Engineering and Information Science in the Departments of Intelligent Systems Engineering and Information Science, Luddy School of Informatics, Computing, and Engineering; core faculty of the Cognitive Science Program; and founding director of the Cyberinfrastructure for Network Science Center (http://cns.iu.edu)—all at Indiana University in Bloomington, Indiana. She is a curator of the Mapping Science exhibit (http://scimaps.org) and she leads the international Human Reference Atlas effort (https://humanatlas.io). She holds an MS in electrical engineering from the University of Technology in Leipzig, and a PhD in computer science from the University of Kaiserslautern. Börner is a Fellow of the American Association for the Advancement of Science (AAAS), a Humboldt Research Fellow, an Association for Computing Machinery (ACM) Fellow, and a Network Society Fellow.

• Knowledge Graphs

Broad, multidimensional business background with expertise in healthcare inclusive of diagnostics, devices and life sciences. During a thirty year tenure in the healthcare industry, have held executive level positions in general management, sales, marketing, business development and international commercial operations. Consciously developed broad expertise across multiple disciplines and geographies, managing commercialization strategies and business operations on a global scale for companies such as Abbott, Digene and Beckman Coulter. Understand the workings of organizations from small start-ups to large, complex corporations. Excel at turning around under-performing operations and leading start-up businesses, global and regional commercialization strategies and product development in regulated markets.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Barry is responsible for overall foundry technology strategy and direction. He holds a PhD in Biological Engineering from MIT, where his thesis focused on refinement of standard biological parts and the interactions between a host cell and an engineered genetic circuit. At MIT, he was involved with the Synthetic Biology Working Group that was instrumental in catalyzing the new field. He also holds an MEngSc in Mechanical Engineering from University College Dublin.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Joan led the non-profit organization, Greater Gift, as CEO. The mission focuses on raising awareness of clinical research, fostering trust through celebrating and expressing gratitude for all participants, and contributing to the well-being of vulnerable children by paying forward the gift of health. A results-driven executive in health life sciences, known for implementing innovative strategies across diverse industries and demonstrating expertise in marketing and operations.

• Digitalization of Clinical Development

Ryan Chandler is a Knowledge Graph Engineer at AbbVie. He holds a PhD in Informatics from the University of Illinois, with a focus on the linguistic and cognitive aspects of knowledge representation. Ryan has dedicated his career to understanding what it means for computers to effectively "know" information. His work at AbbVie centers on developing semantic knowledge graphs and analytic solutions for research and development. He enables research scientists to explore and uncover meaningful insights from large bodies of previously unrelated knowledge and data sources.

• W4: Making Data AI-Ready

Ishwar Chandramouliswaran is a Program Director and technical lead for the strategy, planning, coordination and oversight of establishing a FAIR data ecosystem at the NIH Office of Director, Office of Data Science Strategy (ODSS).

• W1: FAIRification Lab—Applying FAIR Principles to Enhance Data Stewardship

Morris is an AstraZeneca R&D IT business partner and leads target identification IT capabilities, including omics, ELN, LIMS, etc. Prior joining AZ, Morris worked in Accenture and Deloitte as a management consultant for total 8 years. He is specialized in pharmaceutical R&D processes and operations, from early research, clinical operations, clinical supply chain, to pharmacovigilance and even the novel CART processes. Morris received his PhD in chemistry from Duke University, MS in biotechnology from UC Irvine and BS in chemistry from National Taiwan University.

• Digital Biopharma

Biotech executive and board director with extensive experience in leadership, business and corporate development, company setup & building, fundraising, investment, operation, R&D, manufacturing, marketing, and commercialization. Results-driven and passionate about partnerships to develop innovative technologies and products to make a difference in human health. Proven success in partnership, commercialization, and R&D. Experience in technologies, rare diseases, oncology, infectious disease, immunology, vaccines, genetic disorders, cardiovascular, cell & gene therapy, and personalized medicine.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Murtaza is a seasoned healthcare IT leader with extensive experience in the pharmaceutical and biotechnology industries. He has held leadership positions at prominent organizations such as Biogen and Alnylam Pharmaceuticals, where he currently serves as the Head of IT Data Management and Artificial Intelligence. Murtaza possesses a comprehensive understanding of the entire product lifecycle, from research and development to post-commercial operations and manufacturing. With a proven track record of driving innovation, operational excellence, and leveraging technology for measurable business impact, Murtaza is committed to enhancing patient outcomes and accelerating the delivery of new medicines to the market.

• Generative AI

Strategic, visionary leader with an established track record of building and leading multidisciplinary, global Informatics and IS/IT teams, driving change and simplification and delivering value through innovation. Over 20 years’ experience in the biotechnology and pharmaceutical industry working in both Discovery and Development leading projects, managing complex portfolios, driving change programs, identifying opportunities for strategic initiatives, and translating scientific and medical questions into innovative solutions. Areas of particular strength include: strategy development and implementation, translational medicine, biomedical and health informatics, evidence-based decision makings, data and decision science, and "Big Data" exploitation.

• Bioinformatics

Dr. Ciaccio uses Artificial Intelligence and Machine Learning to help accelerate Pharmaceutical Development at AbbVie Biopharmaceutical company. He is a member of the AbbVie RAIDERS (Rapid A.I. Developers) that are dedicated to the implementation of A.I. throughout the company. Mark specifically focuses on Clinical studies, currently working to simulate clinical trial enrollment, write chatbots to help answer regulatory questions, and design machine learning models to implement wearable devices in the clinic.

• Digitalization of Clinical Development

Jim Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT, as well as a Member of the Harvard-MIT Health Sciences & Technology Faculty. He is also a Core Founding Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University and an Institute Member of the Broad Institute of MIT and Harvard. He is one of the founders of the field of synthetic biology, and his research group is currently focused on using synthetic biology to create next-generation diagnostics and therapeutics. Professor Collins' patented technologies have been licensed by over 25 biotech, pharma, and medical devices companies, and he has co-founded a number of companies, including Senti Biosciences, Sherlock Biosciences, and Cellarity, as well as Phare Bio, a non-profit focused on AI-driven antibiotic discovery. He has received numerous awards and honors, including a MacArthur "Genius" Award and the Dickson Prize in Medicine, and he is an elected member of all three national academies—the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine.

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Cloud for AI/ML & Modern Data Science
• Data Science & Analytics Technologies
• Pharmaceutical R&D Informatics
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management
• Digitalization of Clinical Development

Biotech Venture Capital | Captain, United States Air Force (Veteran)

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Matthew Conway, Data Engineering Lead, PMPD, Regeneron Pharmaceuticals, Inc Matt believes that anything is possible with the right data, but that getting the foundational data in place is our biggest challenge. At Regeneron, Matt designs, builds, and maintains a suite of custom applications for enabling process development workflows and increasing data integrity. He enjoys thinking through complex systems and building simple ones. He holds an M.S. in Chemical Engineering from Columbia University.

• Pharmaceutical R&D Informatics

Brett rejoined F-Prime Capital in 2018 and focuses on investments in healthcare technology and service companies. Previously, he led finance, partnerships, and business operations at PatientPing, a healthcare technology company providing real-time admission and discharge notifications to coordinate patient care. Previously, Brett worked at Aledade, F-Prime Capital, and McKinsey & Company. Brett holds an M.B.A. from Harvard Business School and a B.S.E. in Biomedical Engineering from Duke University.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Dr. David Craig is the founding chair of the Department of Integrative Translational Sciences at City of Hope (COH) and the incoming Deputy Director of Translational Sciences at the Beckman Research Institute of COH. He also serves as the Associate Director of Data Science for the COH Comprehensive Cancer Center. Previously, Dr. Craig co-directed the Institute of Translational Genomics and created the Translational Biomedical Informatics Master's Degree program. Dr. Craig's laboratory creates applied genomic and bioinformatic technologies that bridge the gap between engineering, biotechnology, and clinical care. Dr. Craig is an expert in translational genomics, genomic privacy, and bioinformatics, with over 200 publications, 4 patents, and 2 companies founded. He led pioneering studies using whole-genome and transcriptome profiling for treating metastatic triple-negative breast cancer and glioblastoma by developing these methods to support CAP/CLIA-accredited clinical sequencing methods for precision medicine in cancer. Notable publications include work on data privacy (PLOS Genet, 2008), Illumina multiplexed sequencing, sub-clonal evolution in cancer, and deep learning in spatial transcriptomics. Dr. Craig has successfully led large-scale bioinformatics initiatives, including the 1000 Genomes Project and the Accelerating Medicine Partnership, demonstrating his strength in collaborative, multidisciplinary research.

• AI for Oncology, Precision Medicine & Health

Cindy Crowninshield, RDN, LDN, HHC has over 25 years of experience as an expert program developer and project leader for global business and scientific conferences. Since joining Cambridge Innovation Institute (CII) in 2005, she has been responsible for overseeing a portfolio of large-scale events. She started working on the Bio-IT World Conference & Expo in 2007 and is still the lead producer. Cindy has created and delivered over 200 highly-focused executive-level conferences and events attracting international audiences of up to 18,000 delegates, both for CII and other organizations. In addition to her conference work, Cindy has two other parallel careers - 1) Licensed Registered Dietitian and Functional Nutrition Educator in private practice, and 2) Adjunct Instructor, Department of Clinical Research and Leadership at The George Washington University School of Medicine and Health Sciences. She has a BS in Business Management from Fitchburg State University, completed graduate study in nutrition science at Boston University Sargent College, and completed certification with the Institute for Integrative Nutrition & Holistic Health. In 2011, she was one of the founding members of the Women in Bio - Greater Boston Chapter.

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Cloud for AI/ML & Modern Data Science
• Knowledge Graphs
• Data Science & Analytics Technologies
• Generative AI Tools
• Pharmaceutical R&D Informatics
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management
• Digital Biopharma
• Digitalization of Clinical Development

Nirmit is a software engineer at Dyno Therapeutics. He holds a degree in Computer Science with a minor in Biology from Northeastern University. Nirmit is passionate about creating innovative software products and tackling complex problems within the biotech industry and previously interned at Wellframe and Editas Medicine. He has a breadth of experience that spans data pipelining, front-end development, NGS data analysis, and data visualization. Nirmit's current focus is on developing software to augment Dyno's LIMS system in order to allow data to flow seamlessly from the lab to downstream processes.

• Data Management

Vinod Das is a trailblazing expert with a unique blend of technical and functional prowess, honed over two decades of experience in Pharmaceutical Research & Development IT. Currently steering the AI revolution at Bayer Pharmaceuticals R&D, Vinod is leading the charge in integrating Generative AI use cases into the fabric of drug discovery and clinical development. Guided by Vinod’s forward-thinking and insightful consultations, AI innovations have scaled new heights, establishing him as a key influencer shaping the future of the pharma-tech ecosystem. His collaborations with top-tier academic institutions and AI pioneers are pushing the envelope on research, ensuring a sustainable future for AI in Pharmaceuticals. A visionary at heart, Vinod excels at connecting cutting-edge technologies with real-world applications, cementing his reputation as a thought leader who transforms AI-driven initiatives into tangible outcomes. Want to see how AI is transforming the future of pharmaceuticals? Follow Vinod Das—your catalyst for the next generation AI breakthroughs!

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Generative AI Tools
• Pharmaceutical R&D Informatics
• Digitalization of Clinical Development

Cris joined Sanofi Ventures in 2020 to lead investments in digital health and data science innovation. He holds a 20-year track record of building startups, tech innovation platforms, and healthtech deal making with some of the largest organizations in the world. Prior to Sanofi, Cris was a founding member of Johnson & Johnson Innovation and Global Head of Digital Innovation since 2013. He held chief digital and data responsibilities, driving digital health strategy and new venture partnerships throughout J&J Innovation spanning the Pharmaceutical, Consumer and Medical Device businesses.​ Previously, Cris led emerging technology programs within research informatics at Novartis for six years. With entrepreneurial DNA, Cris is notably known for his role in the innovation economy since co-founding Ultra Light Startups, one of the largest and oldest startup venture pitch accelerators in the U.S, catalyzing hundreds of companies in Boston, NYC, and Silicon Valley, leading to several acquisitions by major tech companies. Cris was named 40 Under 40 by the Boston Business Journal and a Top 40 Healthcare Transformer by MM&M Magazine.​ Cris currently serves on the boards of Aetion, Click Tx, Empatica, Medisafe, Nucleai, and Omada. Cris holds a M.Sc. in Computer Information Systems from Boston University and a B.S. in Business Administration from Suffolk University.​

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

A former neuroscience researcher, Andrea’s portfolio career has included leadership assignments at the intersection of science, technology and business development. She has built and led informatics and scientific teams across the entire pharmaceutical value chain. Most recently, Andrea focused on building the Pharma Artificial Intelligence market at NVIDIA. Through this experience she has travelled the world advising biopharmaceutical, academics, research institutes, and startups in the potential of machine learning and artificial intelligence across every discipline in our industry. Prior to her role at NVIDIA, Andrea held leadership positions at the Broad Institute of Harvard and MIT, Amgen, and Roche. In the last three years, Andrea’s work at Eli Lilly & Company has focused around empowering the LRL Research organization with greater computational, analytics-intense experimentation to raise the innovation of our scientists. As the Global Head of Data Sciences and Advanced Analytics, Andrea leads four organizations: The High-Performance Computing Team, the Data Engineering team, the AI/ML team and the Translational Informatics team for LRL. Additionally, Andrea serves as a strategic advisor for the NIH HubMap Advisory Team. She has a B.S. in Animal Physiology from UC Davis, a Master’s in Health Administration from University of San Francisco, and an MBA from MIT Sloan. Her leadership has gained her international recognition as a leader in Big Data, Artificial Intelligence and Data Sciences.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

At MIT, I lead a team dedicated to managing data for several high-impact, interinstitutional projects focused on cancer research, infectious diseases, and environmental remediation. Our team supports researchers in data release at publication, facilitates data sharing across consortia, and addresses diverse data management requirements. The MIT BioMicro Center oversees data management for four major grants: IMPAcTB, MIT SRP, CSBC, and MetNet. Additionally, I serve as the BreakThroughCancer MIT-KI (Koch Institute for Integrative Cancer Research) Data Coordinator, where I perform similar data management duties.

• Digital Biopharma

DESAPHY Jeremy obtained a master in Chemoinformatics at the University of Strasbourg in 2010, followed by a PhD in structural chemogenomics in 2014 where he developed tools to detect and compare protein/ligand binding sites and binding modes in crystal structures. In 2014, he was hired at Eli Lilly and Company to build innovative capabilities and analytical tools for crystal structures. In 2018, he joined as a scientific data lead the Genetic Medicines group where he is in charge of creating a data infrastructure and algorithms to help in the development of new therapeutic modalities.

• Pharmaceutical R&D Informatics

Lena is Lead for Semantic Data Products at Bristol Myers Squibb. She is a data science and bioinformatics expert with extensive experience in delivering value to her clients through effective data governance, data analysis, and predictive AI, particularly within the R&D and Healthcare sectors. With proficiency in FAIR principles, she actively contributes to pre-competitive consortia such as the Pistoia Alliance, ensuring that her clients are equipped with awareness of industry standards. Lena holds a PhD in Bioinformatics from Universidade Nova de Lisboa (2011) and an MS in Biology from Universidade de Lisboa (2004). She has received 9 awards, including the Elsevier Silver Coin and the NASA Space Apps Challenge winner. Lena has authored over 50 peer-reviewed publications in healthcare and life sciences, accumulating more than 1000 citations. Additionally, she has a patent to her name and has delivered 5 keynote addresses.

• Knowledge Graphs
• Generative AI Tools
• Pharmaceutical R&D Informatics

Epic Ding is Sr. Manager, Research Informatics, Gilead Sciences. Epic joined Gilead in 2022 to overhaul Gilead's biologics informatics ecosystem to support Gilead's large molecule research expansion. Prior to Gilead, Epic worked at Amgen Research informatics team for 17 years where he designed, built, implemented, and supported a full range of informatics systems from discovery/production workflow, registration, inventory, assay data management, in vitro/in vivo DMPK data management, which spread both small molecule and large molecule. Epic holds an M.S. in Computer Science from Stanford University.

• Digital Biopharma

Achal is a Lead Data Scientist (DS |||) working in Innovation and Digital Health at Bristol Myers Squibb. He is an experienced data science and analytics expert with background in computer science and engineering. He has graduated from Indian Institute of Information Technology Guwahati and was a Visiting Research Scholar at Imperial College London before joining industry. His previous research has covered the interface of applied ML, healthcare, and bio-medicine.

• Generative AI

Peter Doerr is leading the presales team at metaphacts, a subsidiary of Digital Science specialized on Knowledge Graphs. After completing his PhD in mathematics, his career took him through IT and telecommunications where he worked in senior commercial roles as Vice President for Telefonica and Huawei before returning to a science-driven environment. At Digital Science, as VP corporate solutions, he worked closely with the largest customers to align applications and customer needs.

• Knowledge Graphs

Ms. Dolcetti boasts over 15 years of multifaceted expertise in Global Health Tech, Digital Innovation, and Artificial Intelligence, with a background spanning startups, Fortune 500 companies, academia, and management consulting, including a tenure at Boston Consulting Group. Specializing in life sciences, she excels in corporate strategy, private equity/venture capital, partnerships, and commercialization, showcasing a knack for successful product launches. Her subject matter expertise spans precision medicine, diagnostics, genomics, oncology, and the integration of AI, informatics, data analytics, cloud infrastructure, and SaaS solutions. A seasoned professional in navigating the convergence of healthcare and technology, Sara brings strategic acumen to the evolving landscape of digital health and medical devices. Continuously staying abreast of industry trends, she is a driving force committed to advancing healthcare through innovative technological solutions.

• W2: Foundations of Quantum Computing in Drug Discovery
• W5: Advanced Applications and Roadmap for Quantum Computing in Pharma

Kory Draughn currently serves as Chief Technologist of the iRODS Consortium at RENCI (Renaissance Computing Institute) and oversees the develoment team and maintains the technology roadmap. He aims to empower the community by providing better tools for administrators and libraries for developers. Kory is interested in distributed systems, performance, design, algorithms, and open source software. Kory holds a B.S. in Computer Science from East Carolina University and a M.S. in Computer Science from New Jersey Institute of Technology.

• Data Management

Drew Dresser is a Director of Cloud Engineering at Flagship Pioneering, where he provides guidance on building cloud solutions and serves as the lead architect for the company's cloud platform. Before joining Flagship Pioneering, Drew worked as a Senior Solutions Architect at Amazon Web Services (AWS), where he provided technical expertise and designed solutions for healthcare and life sciences startups. He has also worked in AWS Professional Services, where he led customer engagements to develop cloud-native architectures and next-generation sequencing pipelines. Drew has a bachelor's degree in Mathematical Economics from Wake Forest University.

• Cloud for AI/ML & Modern Data Science
• Software Applications & Services

Frank Dullweber is an experienced life science professional. Due to his long-term experience in pharmaceutical research, he has an in-depth understanding of data domains that are relevant for pre-clinical and clinical drug discovery and clinical development. He graduated with a PhD in cheminformatics and obtained a master degree in clinical research management. Until recently, he worked in bioinformatics and is now a member of the Center of Excellence for Digital Transformation in the clinical development domain.

• Digitalization of Clinical Development

Chris Dwan is a technologist who has spent more than two decades supporting the life sciences with a focus on genomics. He was the first employee at BioTeam, built the IT and data infrastructure for the NY Genome Center, led Research Computing and IT at the Broad Institute, and most recently served as the SVP of Production Bioinformatics at Sema4. Chris is currently an independent consultant. He provides leadership in IT, develops digital strategies, authors technology assessments, and coaches / mentors emerging leaders in biotech, pharma, and health care. His clients have included Arena BioWorks, Moderna, the Johns Hopkins School of Medicine, the INOVA Health System, NASA, and Cray.

• Data Platforms & Storage Infrastructure

No bio available.

• AI for Drug Discovery & Development

With over two decades of diverse professional experience, my career has encompassed roles in software development, leadership, and high-energy physics research. I have had the privilege of leading multi-functional teams, shaping product strategies, and managing integrated service ownership for data lifecycle management and computing technologies at Roche. My journey began in software development at KLA-Tencor, where I managed decentralized teams and played a pivotal role in evolving hardware control software architectures. Prior to my industry career, I contributed to groundbreaking research at BaBar and Stanford Linear Accelerator Center, focusing on data analysis, simulation, and collaboration within international research programs. My academic journey culminated in a PhD in High Energy Physics, and I was recognized for my academic achievements with the 1998 ADRERUS award for the best international thesis of the Rhine Valley Universities. Throughout my career, I've upheld a steadfast commitment to building trust, driving outcomes, and embracing a product management mindset centered around empathy for consumers and structured decision-making.

• Data Platforms & Storage Infrastructure

In his role at Google Cloud; Bill oversees a strategy and organization whose goal is to bring accelerated cloud-based scientific solutions to the fast-growing and ever-evolving Biotechnology segment. The Google Cloud Biotech organization aims to provide value from the top venture firms investing in early-stage biotechnology doing pre-clinical research through the numerous commercial opportunities; IPO, licensing partnerships, and commercialization. In support of the biotech ecosystem the organization partners with industry leaders, technology, and solution providers to assure that Google Cloud can deliver the best environment for the rapid evolution of science and return for its investors. The biotech solution organization and its partners deliver a number of solutions which lower the cost of scientific research across numerous modalities by utilizing Artificial Intelligence, Big Data, Gene Editing, Precision Medicine, Gene Sequencing as well as Synthetic Biology. Bill has over 15 years of experience in the biotech and biopharma ecosystem where he has led similar organizations at various startups and at EMC & Dell Technologies. He is a former founder of the Life Sciences User Groups in Cambridge, MA and a current member of the Massachusetts Biotech Council. He has a degree in Management Information Systems and executive certifications from Babson College.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Fernanda Foertter is currently the Director of Developer Relations at Voltron Data. She previously held roles as the Senior Scientific Consultant for BioTeam and GPU Developer Advocate for Bioinformatics at NVIDIA in the Healthcare group where she fostered an emerging community in AI and GPU computing. Before NVIDIA, Foertter held roles as an HPC Data Scientist in the Biomedical Sciences and Engineering group and was an HPC Programmer and Training Coordinator at the Oak Ridge National Lab's Leadership Computing Facility. She participated in the CORAL project that selected Summit as the next supercomputer to replace Titan, was co-PI of Kokkos Exascale Computing Project, served in OpenACC and OpenMP language standards, and is the “inventor” of the GPU Hackathon training series. Other interests include the intersection of HPC and AI, facilitating data integration workflows, and productivity in scientific application development.

• W4: Making Data AI-Ready
• Data Platforms & Storage Infrastructure

As the Head of End-to-End AI Foundations for Large Molecules Research at Sanofi, Dr. Fomekong Nanfack spearheads strategic and operational AI and digital initiatives to revolutionize large molecule drug discovery. Yves is at the forefront of numerous digital transformation endeavors at Sanofi, driving the increased utilization and effectiveness of AI in drug discovery. One notable initiative he spearheads is Biologics-AI Moonshot aimed at elevating the role and influence of AI in Antibody and Nanobody discovery. Prior to joining Sanofi, Dr. Nanfack served as the Head of Structural and Digital Drug Discovery at EMD Serono. There, he directed a team of computational scientists and structural biologists, driving advancements in both large and small-molecule drug discovery across diverse therapeutic domains. He was instrumental in digitally transforming EMD Serono's approach to large molecule research by integrating advanced data analytics and mining platforms. Furthermore, he pioneered the application of AI/ML and predictive modeling techniques for the discovery and optimization of antibody-based molecules, contributing significantly to multiple projects that progressed to clinical development stages. Dr. Nanfack holds a master’s in computer sciences from the University of Geneva, Switzerland, and PhD in computational biology with a specialization in systems biology from Universität van Amsterdam, The Netherlands.

• Digital Biopharma

Felix Francis is a seasoned leader in Bioinformatics, Data management and advanced analytics with over 14 years of expertise in these domains across the pharmaceutical, biotech, and academic sectors. Currently, he is the Senior Manager of Data Management and Analytics at Takeda, where he leads the development of informatics solutions for drug discovery and development. Felix has led significant bioinformatics and data management projects at Abcam, creating bioinformatic tools for immune repertoire sequencing and antibody discovery. He holds a Ph.D. in Bioinformatics & Systems Biology. Felix has held leadership roles, including co-leading Takeda's Innovation (X) team and is an active member of professional societies and has served as an invited reviewer for various publications and on panels for conferences in the areas of informatics and analytics.

• Bioinformatics

Alyssa Fronk, PhD is the Director of Computational Biology at Envisagenics, a biotech company in NYC using artificial intelligence and machine learning to leverage RNA sequencing data for RNA drug discovery and development. Alyssa’s team focuses on extracting meaningful insights from complex biological data by building interpretable machine learning algorithms and functional pipelines to pave the way for the development of novel RNA-based therapeutics. Prior to Envisagenics, Alyssa received her PhD in molecular and computational biology from Albert Einstein College of Medicine, where she studied the molecular mechanisms underlying RNA splicing regulation.

• AI for Drug Discovery & Development

With >10 years experience in Research Informatics, a passion for science and human-centric digitalization in drug discovery, Angelika Fuchs is currently leading the Data Products & Platforms chapter in Data & Analytics of Pharma Research and Early Development.The chapter brings together all competencies required to design, build, operate and evolve pRED's digital landscape and aims to enhance the full scientific data pipeline from structured data capture to powerful data integration and efficient data interrogation in order to create and develop successful drug molecules as efficiently as possible. Before the current role, Angelika led the Discovery Informatics organization in Roche pRED as well as several global research informatics projects in the space of Digital Pathology and Lab Automation.

• W4: Making Data AI-Ready
• Pharmaceutical R&D Informatics

Results-driven R&D Informatics Program Lead/Product Owner building digital and data-driven business outcomes by providing long and short-term IT strategies. Experience in establishing data-centric culture and community, building fully automated instrument data integration capability by establishing information and data model aligning with FAIR data principles and transformations to run advanced analytics and data-driven insights to select fast and the best drug candidate for Pharma R&D. Accomplished gene sequence analysis for GWA and CNV using different Bioinformatics tools. Built Artificial Neural Networks by using Machine Learning Algorithm for Ribosome Binding Site (RBS) search. Excellent analytical, problem-solving, and leadership skills, coupled with outstanding communication and interpersonal skills with expertise in managing global matrixed teams, and relationship building with senior leaders of the organization by delivering clear and effective executive-level communications and updates.

• Generative AI Tools

Brendan Gallagher is the Head of Business Development for Sentieon Inc. Brendan has almost 10 years’ experience in bioinformatics software tools. Prior to joining Sentieon, Brendan helped develop the approved precision medicine, “Lutathera,” in the chemistry/wetlab at BioSynthema. Lutathera is a peptide radionuclide receptor therapy for cancer patients, developed at BioSynthema in St. Louis and currently marketed by Novartis.

• AI for Oncology, Precision Medicine & Health
• Bioinformatics

Driven by intellectual curiosity, Victoria is focused on improving healthcare by connecting patient-centricity, digital health, and real-world evidence through innovation and digital transformation to evolve clinical research. In her current role as Global Head of Data Governance & Insights, Victoria is accountable for shaping the data strategy and data governance for Clinical Development and Operations. Victoria enjoys connecting with others who support he use of data to generate insights, especially with innovative applications to advance healthcare.

• Digitalization of Clinical Development

A Product Leader with a demonstrated history of delivering clinical IT transformations for pharma, biotech/CROs with a Wharton Management Development Program, Kellogg Product Strategy and Stanford Advanced Program Management from Stanford University. He is a big believer in product innovation and leads large teams in product development using SAFe Agile methodologies. He is an ex-IQVIA/ex-Medidata with 20+ years in clinical IT. Anand is a tech savvy leader with interests in AI, big data, blockchain and use them to address the challenges faced by the life sciences industry. Anand loves participating in hackathons and social innovation activities in the life sciences/ healthcare space. More recently Anand was a semi- finalist in 'HITLAB Breakthrough One' Challenge featuring EZTrialFinder™, a Gen AI driven innovative solution enable patients find clinical trials from their mobile phone.

• Data Platforms & Storage Infrastructure

No bio available.

• AI for Drug Discovery & Development

Matthew Gerring works in Computational Science for Jackson Laboratory. He has an interest in image analysis, graph databases and durable workflows. https://www.jax.org/people/matthew-gerring

• Cloud for AI/ML & Modern Data Science
• Knowledge Graphs

Molly is an Origination Partner at Flagship Pioneering, working as part of a venture-creation team to found and grow companies at the intersection of biology and machine learning. Molly serves as co-founder & chief strategy and chief innovation officer of Generate:Biomedicines, a Flagship Pioneering company, where she has served many roles from R&D to corporate strategy, platform and data strategy, and launching an innovation group, called G:Labs that explores novel applications of The Generate Platform. Through her role in Flagship Labs, Molly has contributed to the launch and growth of Tessera Therapeutics and Cobalt Biomedicines, which was merged into Sana Biotechnology. Molly’s work has resulted in multiple pending patents and publications, including articles in Science and Nature. Molly was honored in 2020 in Endpoints News' 20 under 40 list in biopharma and in 2021 in Business Insiders’ list of 12 young serial entrepreneurs building the next generation of biotech startups. Molly received a PhD in computational and systems biology from Washington University in Saint Louis in the Center for Genome Sciences, with the support of a National Science Foundation Graduate Research Fellowship. At Washington University, Molly collaborated with St. Louis Children's Hospital to study the effects of early-life interventions on development of the preterm infant gut microbiome and health outcomes.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Mr. Goldberg is an Operating Partner of Arsenal where he focuses on networking and sourcing transactions for the healthcare team. Prior to joining Arsenal in 2014, Mr. Goldberg was a Managing Director, Corporate Development of Endo Pharmaceuticals. Previously, he was a founding Partner of ProQuest Investments and the founding CEO or founder of three biotechnology companies that were acquired or taken public. In addition, he also held executive positions at Becton Dickinson and at GSK. He serves on Dana Farber Cancer Institute Visiting Committee and board of NIH/Cambridge/Oxford Scholars program.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Miguel received his PhD in Biophysics from University College London, where he investigated the microenvironment of solid tumors using MRI. After a short stint at a biotech start-up, Miguel joined AstraZeneca where he initially applied advanced analytics to support late-stage study teams. Miguel's work is now mainly focused in Knowledge Graph applications in the Early Oncology setting.

• Knowledge Graphs

Robert C. Green, MD, MPH is Professor of Medicine (Genetics) at Harvard Medical School and a physician-scientist who directs the G2P Research Program at Brigham and Women’s Hospital and the Broad Institute. Dr. Green is internationally recognized for research and policy efforts accelerating the implementation of genomic/precision medicine. Education and Training: Dr. Green graduated Amherst College and University of Virginia School of Medicine, with MPH in epidemiology from Emory University School of Public Health. His specialty training was at Harvard Medical School residencies and he is board certified in both neurology and medical genetics. Research Achievements: Dr. Green led the first experimental trials disclosing common complex disease risk (REVEAL Study) and the first prospective studies of direct-to-consumer genetic testing services (PGen Study). He currently leads and co-leads the first NIH funded randomized trials of sequencing in adults (MedSeq Project), newborns (BabySeq Project), and active duty US military personnel (MilSeq Project). He created the concept of aggregate penetrance of genomic variants in prospective population cohorts and is demonstrating the feasibility of genomic sequencing in healthy newborns, paving the way for humans to gain lifelong medical benefits from genomics. With continuous funding from NIH for 26 years he has published more than 300 papers with an h index of 90. In 2014, he won the Coriell Prize for Scientific Achievement in Personalized Medicine, and in 2019 was named by BIS Research as one of the 25 most influential voices in precision medicine. Since joining the Harvard Medical School faculty in 2011, the G2P research team has been awarded research support of over $49 million. Research Leadership: Dr. Green recently co-chaired the Steering Committee of both the Clinical Sequencing Exploratory Research program (18 NIH grants, over 300 investigators), and the Steering Committee of the Newborn Sequencing in Genomic Medicine and Public Health program (4 NIH grants, over 100 investigators) and is a co-investigator on the Boston site within the Electronic Medical Records and Genomics Network. He is Associate Director for Research of Partners HealthCare Personalized Medicine and is leading the development of protocols for return of genomic results for the All of Us Research Program of the United States Precision Medicine Initiative and the Google/Verily Project Baseline. Policy Leadership: Dr. Green is accelerating the worldwide implementation of medical genomics. He was lead author on the influential recommendations for managing incidental findings in clinical sequencing from the American College of Medical Genetics and Genomics and contributing author on recommendations for managing incidental findings in research biobanks among participants and among family members of participants. He is a Board Member of the Council for Responsible Genetics and works within the Global Alliance for Genomics and Health and the All of Us Research Program on designing efforts to return research information, particularly genomic information, to research participants. Clinical Care: Dr. Green directs the Preventive Genomics Clinic at Brigham Health, providing evidence-based genomic and multi-omics evaluation to early adopters seeking to anticipate and prevent future illness. Entrepreneurship: Dr. Green co-founded Genome Medical, a telegenomics technology and services company providing genetics expertise to patients, providers, employers and healthcare systems. Presentations & Media: Scientific plenary presentations include American College of Medical Genetics/Genomics, Cold Spring Harbor, AGBT, European Society for Human Genetics and BioData World. Presentations to business include Forbes Healthcare Summit, World Science Festival, Future of Genomic Medicine, Exponential Medicine, Festival of Genomics, Aspen Ideas Festival, SXSW, Asian Healthcare Leadership and JP Morgan. His work and commentary have been featured on PBS television/radio, NBC Nightly News, CBS Sunday Morning, Today Show, CNBC, the Doctors, New York Times, Wall Street Journal, Time Magazine, New Scientist, FastCompany, GenomeWeb, Gizmodo and Buzzfeed. Research findings from Genomes2People Research are highlighted in these podcasts, blog posts and videos. Research Support: Dr. Green’s research is supported by grant funding from the National Institutes of Health, the Department of Defense, the Snite Foundation and the Franca Sozzani Fund for Preventive Genomics. Disclosures: Dr. Green receives compensation for advising the following companies: AIA, Embryome, Genomic Life, Grail, Humanity, Kneed Media, OptumLabs, Plumcare, Verily; and is co-founder of Genome Medical, Inc, a technology and services company providing genetics expertise to patients, providers, employers and care systems.

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Cloud for AI/ML & Modern Data Science
• Data Science & Analytics Technologies
• Pharmaceutical R&D Informatics
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management
• Digitalization of Clinical Development

Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of experience in the healthcare and tech sectors. Luba has served as the Chief Executive Officer and Chair of the Board of Kojin Therapeutics, a leader in ferroptosis. She currently serves as the Managing Partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has founded, investing and building companies across therapeutics, diagnostics, and digital sectors. She has also served as a lecturer at Harvard University in the School of Engineering and Applied Sciences. Ms. Greenwood has extensive board experience globally and serves on public and private boards, across multiple industries, including healthcare and tech, and has successfully contributed to the growth and profitability of numerous organizations, bringing her operational, industry, and financing expertise. She has a proven track record of building world-class teams and companies, building SABs with renown scientists and industry leaders, driving digital transformation and artificial intelligence initiatives, guiding companies through mergers & acquisitions, complex business development transactions, financing, and organizational change and scaling. With a strong understanding of board dynamics and corporate governance best practices, and as a former lawyer, she has also guided organizations through compliance, activist actions, and human resources challenges. She has served as Chair of the board as well as on the Compensation, Audit, and Nomination committees of a number of companies including In8Bio (INAB), BenchSci, Swiss-based Stalicla, Abcam (Abcam), where she has spearheaded the sale to Danaher (DHR), and non-profit, Massachusetts Biotechnology Council (MassBio). Ms. Greenwood has previously served in leadership roles at Google Life Sciences (Verily) and as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also led diagnostics BD and established and led the East Coast Innovation Hub. Luba has led $5B+ in M&A, BD deals, and investments across multiple therapeutic areas, diagnostics, life sciences, and tech sectors globally. She has also co-founded and advised biotech and digital health companies in the immunotherapy, AI/ML, women's health, and microbiome space, including Luca Biologics. Her invaluable contributions to the healthcare industry have earned her recognition as a thought leader and a trusted advisor to CEOs of leading academic centers worldwide, including the Dana Farber Institute and Wyss Center for Bio and Neuroengineering in Geneva. She is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst and serves on Investor Committee for the National Cancer Institute. With a background as a former lawyer at Wilmer Cutler Pickering Hale and Dorr and expertise in regulatory, policy, and intellectual property matters, Ms. Greenwood brings a unique perspective to the table. Her commitment to advocating for women in science and technology has garnered several awards and honors, including the Science Club for Girls Catalyst Award.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Sofia is an investor in the Cambridge office, where she focuses on healthcare and biotech. Sofia began her career as a consultant at Bain and Company, where she worked on strategy, operations, and due diligence projects across healthcare and technology. Prior to joining Bessemer, she was an investor at BoxGroup Ventures and the co-founder and President of Nucleate Bio, a national life sciences entrepreneurship program helping PhDs, Post-docs, and students commercialize scientific projects. Sofia earned her MBA from Harvard Business School and her BA with high honors in Chemistry from Harvard University. While in school, she conducted research alongside Bob Langer, a serial entrepreneur and one of 12 Institute professors at MIT widely recognized for his contributions to drug delivery and tissue engineering fields.

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Cloud for AI/ML & Modern Data Science
• Knowledge Graphs
• Data Science & Analytics Technologies
• Generative AI Tools
• Pharmaceutical R&D Informatics
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management
• Digital Biopharma
• Digitalization of Clinical Development

Rajarshi Guha is currently a Senior Director in Data & Computational Sciences at Vertex Pharmaceuticals. The groups remit is broad, covering method development for small molecule informatics, genomics and image analytics. With over 15 years of experience in handling, analyzing, and visualizing chemical information, he has developed novel algorithms for the analysis and visualization of chemical data types, large scale infrastructure projects (Trans-NIH RNAi screening facility, Pharos, BARD), and worked on small molecule screening programs for rare cancers and infectious diseases. He is also active in the Open Source cheminformatics community as well as the ACS Division of Chemical Information. His work has led to over 140 peer-reviewed publications and more than 30 invited lectures over the last decade. Prior to joining Vertex, he held positions at NCATS NIH and the School of Informatics at Indiana University, Bloomington.

• Cloud for AI/ML & Modern Data Science

Rishi has over 15yrs of experience in Pharma in various capacities. He is currently a Director within the GDC/CADD group at Novartis Institutes for Biomedical Research, at Cambridge, MA. He is leading several efforts in developing and applying cheminformatics, data science, AI/ML and molecular modeling methods for advancing drug discovery and development. Prior to Novartis, Rishi was at AbbVie where he led the Data Science and Informatics group. At AbbVie, he conceptualized and developed a web-based infrastructure to expose suite of Cheminformatics tools called AIDEAS. He developed and deployed machine-learning models for a variety of bioassay data including ADMET endpoints. In his extended role within Competitive Intelligence (CI), Rishi developed web based visual-analytics for several organizations.

• Generative AI

Dr. Iman Hajirasouliha is an Associate Professor of Computational Genomics at the Institute for Computational Biomedicine at Weill Cornell Medicine of Cornell University and a member of the Englander Institute for Precision Medicine and the Meyer Cancer Center, New York, USA. He completed a Postdoctoral Scholarship at the Computer Science Department, Stanford University, and a Simons Research Fellowship at the University of California, Berkeley. His research focuses on computational genomics, computational digital pathology, large-scale sequence analysis, and characterizing somatic variations and intra-tumor heterogeneity in cancer. Iman received his B.Sc. in Computer Engineering from Sharif University and his M.Sc. in Computing Science from Simon Fraser University (SFU). He obtained his Ph.D. with Exceptional Recognition from SFU and also held a postdoctoral appointment at Brown University. Iman received a Simons-Berkeley Research Fellowship, an NIGMS Maximizing Investigators' Research Award, and an Irma T. Hirschl Career Scientist Award. He is on the program committee of several bioinformatics conferences, including ISMB and RECOMB Link: www.imanh.org

• AI for Oncology, Precision Medicine & Health
• Bioinformatics

No bio available.

• W6: AI in Antibody Design

No bio available.

• W1: FAIRification Lab—Applying FAIR Principles to Enhance Data Stewardship

Andrew Hedin is a partner in Bessemer’s Cambridge office where he focuses on investments broadly across the healthcare ecosystem, including new biotech therapeutics as well as software and services sold to healthcare verticals. Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund where he invested in early-stage biotech and digital health technologies, as well as Leerink Partners as an advisor to the biopharma industry. He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Result-driven scientific software engineer with 15+ years of experience including 13 years in the pharmaceutical research environment. Demonstrated skills in designing, architecting, implementing and supporting enterprise-level applications hosted on Cloud and On-premises technologies. Collaborating closely with software engineering teams as well as with project stakeholders, end-users and vendors. Actively working on 20+ large IT projects across the research value chain to achieve major improvements including digitalisation projects.

• Cloud for AI/ML & Modern Data Science

Jennifer's strong foundation in math and biology naturally led to a career in data science. Beginning as a Scientific Applications Developer over 15 years ago, today she is the Associate Director of Scientific Informatics at Eisai G2D2. In this role, she focuses on processes that transform data into the knowledge needed to drive scientific research. Outside of work, Jennifer blogs for TouringPlans, a company specializing in data-driven vacation planning for Disney parks. She lives north of Boston with her husband, children, and an assortment of pets.

• Pharmaceutical R&D Informatics

Angela has dedicated her career to the design, configuration, installation, support, and management of control systems and data historians. She confesses to being obsessed with Operational Technology and Data Management. In her role at Regeneron, Angela supports the Preclinical Manufacturing & Process Development group, specializing in lab equipment ETL and IT/OT convergence. She holds a Bachelor of Engineering in Chemical Engineering from the University of Salford, UK.

• Pharmaceutical R&D Informatics

Dr. Hinkle established research informatics at Alnylam in 2007 and is responsible for all aspects of in-silico design of RNAi therapeutics as well as the compute infrastructure to support large scale human genetics. Greg was a graduate student of Lynn Margulis, did his post-doc at the Marine Biological Laboratory in Woods Hole, Massachusetts, and was an academic teaching molecular evolution for 3 years. In his spare [sic] time, he builds boats.

• Cloud for AI/ML & Modern Data Science

Ying Huang is the Director, Bioinformatics at Gilead Sciences, where he leads data science efforts to support large molecule research, including the development of analytics tools and AI applications in biologics discovery. Ying joined Gilead in 2023, bringing 10+ years of experience from his previous roles at Regeneron and Pfizer, where he advanced through positions with a focus on integrative data analysis and AI/ML applications. He holds a PhD in Bioinformatics from Tsinghua University.

• Digital Biopharma

Mike Iarrobino is Director of Product Management for CCC’s award-winning content and rights workflow suite, RightFind®. He has previously managed marketing technology and regulatory search products at FreshAddress, Inc., and HCPro, Inc. He speaks at webinars and conferences on the topics of data pipelines, information discovery, and knowledge management.

• Data Science & Analytics Technologies

Dr. Kevin M. Ileka is Associate Director, Worldwide Immunology Communications at Bristol Myers Squibb (New Brunswick, NJ). He also is a STEM advocate and serves on the Executive Board of the National Organization for the Professional Advancement of Black Chemist and Chemical Engineers (NOBCChE). Dr. Ileka earned his Ph.D. in chemistry from the University of Michigan where he focused on RNA/DNA structure analysis. He received his B.S. degree in chemistry from St. John’s University (Queens, NY).

• Data Science & Analytics Technologies

Dr. Yuval Itan is an Associate Professor at the Icahn School of Medicine at Mount Sinai, NYC. He specializes in human disease genomics, pioneering innovative machine learning approaches for assessing the functional impact of human genetic variants. Additionally, he conducts genome- and phenome-wide associations within major biobanks across diverse human populations, leveraging genomic and electronic health records data.

• AI for Oncology, Precision Medicine & Health

No bio available.

• Cloud for AI/ML & Modern Data Science
• Data Science & Analytics Technologies
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management

Nick Juty is a Senior Research Technical Manager in the eScience Lab, based in the Department of Computer Science at The University of Manchester. He is involved in numerous EU projects relating to aspects of FAIR and interoperability, particularly with respect to identifier systems and metadata. Nick previously worked at EMBL-EBI where he helped create the identifiers.org identifier resolution system. Nick holds a PhD in Biochemistry from the University of Southampton.

• W1: FAIRification Lab—Applying FAIR Principles to Enhance Data Stewardship

No bio available.

• Digitalization of Clinical Development

Milind Kamkolkar is a seasoned entrepreneur, investor, Board Member, and Fortune 500 C-suite executive. Milind’s career has spanned big pharma, big and boutique management consulting organizations, and numerous technology startup companies focused on the intersection of health, AI and data. Currently, Miland is a Venture Partner at RA Capital. RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. Prior, Milind was co-founder and Chief Business Officer of Network Bio, a company transforming precision medicine by developing the US Biobank. Before this, Milind co-founded Paradigm, a company that raised 203.5M USD for Series A in 2022, focused on creating equitable access to clinical trials as a treatment option for any patient, anywhere. Prior to that, Milind was the CDO of Cellarity, a Flagship Pioneering biotechnology company who are rewriting the rules of drug creation by unraveling the complexity of disease biology at the cellular level. At Flagship, Milind also supported numerous AI for drug discovery initiatives. Milind was the first enterprise Chief Data Officer in the pharmaceutical industry at Sanofi and as VP of AI & Behavioral Science, launched the role of AI & Data science at an enterprise level at Novartis. Milind is also on the Board of Directors of Castor and Turbine, two tech companies specializing in improving clinical trials and drug discovery. Milind is a featured speaker; TedX, Top 100 Leaders in AI, Business Transformation Top 150 Leaders, and a thought leader in Digital Health, AI & Big Data. He has also served as an Honorary Lecturer for physician entrepreneurship at BartsX, Faculty at Exponential Medicine, and a Former Special Advisor to the UN Global Sustainable Development Goals. In his spare time, Milind works on technology approaches to overcome challenges facing neurodiverse needs, sustainability, and wellness.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Petrina Kamya, PhD, is the Head of AI Platforms and President of Insilico Medicine, Canada an end-to-end artificial intelligence-driven drug discovery company. Before joining Insilico, Dr. Kamya spent eight years in various roles at Chemical Computing Group that involved scientific and business-related aspects of preclinical drug discovery. In addition to establishing the corporate strategy for the sales and business development of molecular modeling software for academia, she also played an active role as an application scientist working on real-world discovery projects and finally in a senior role in strategy and business development for pharma and biotech companies. Following her time at CCG, Petrina moved to Certara as a Market Access Manager, where she learned first-hand the challenges of getting drugs to market. Petrina has been with Insilico Medicine since August 2020. She holds a PhD in Chemistry (specializing in computational chemistry) from Concordia University.

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Pharmaceutical R&D Informatics
• Digitalization of Clinical Development

Gurpreet has been working as a Program manager for more than 14 years with experience of 28 years in IT technical project planning and implementation industry. He helped establishing the PMO at his company and has managed many complex projects globally. Gurpreet works closely with customers and portfolio managers to help them resolve specific issues and problems regarding the programs & projects. Gurpreet has MBA Degree from Edinburgh Business School and Bachelor of Engineering in Computer Science.

• Software Applications & Services

Dr. Karanicolas is a Professor of Molecular Therapeutics at Fox Chase Cancer Center. He was granted a Ph.D. from The Scripps Research Institute in 2003, for his work using molecular dynamics simulations to study protein folding. He then moved to a postdoc at the University of Washington, where he studied protein design and added a wetlab component to his research. He started his lab at the University of Kansas in 2008, focusing on developing structure-based approaches for modulating protein function using small molecules. He moved his lab to Fox Chase in 2016 to pursue translational applications of his research.

• Cloud for AI/ML & Modern Data Science

Ken Karapetyan, who holds a PhD in Organic Chemistry, has refined his product management and cheminformatics expertise by ensuring software products align with market needs. As Associate Director of Product Development at Novartis, he drives the identification and execution of GenAI use cases for drug discovery, leading initiatives from ideation to proof of concept and MVP delivery.

• Generative AI Tools

Sukru currently leads the IT organization at AbbVie’s multiple sites in Massachusetts with two teams focused on research informatics supporting early R&D and biologics development/CMC. At Abbott/AbbVie for over 10 years, he started in the discovery organization focused on data and bioinformatics supporting biologics research and ultimately transitioned to the information research R&D IT organization in 2016. His prior experiences and roles span across the bench and clinical sciences as well as IT, software engineering, and data science. Sukru has a B.A. in Biochemistry and Molecular Biology and a M.S. in Bioinformatics, both from Boston University.

• Digital Biopharma

As a venture partner at Third Rock, John works with the platform team to develop, implement, and refine technology roadmaps for companies across our portfolio with a focus on the identification and integration of drug discovery and development technology platforms. Prior to joining Third Rock, John was the vice president of information technology and informatics at Infinity Pharmaceuticals where he was responsible for information systems, software development, computational science, biostatistics, clinical data management, and clinical informatics. Over the course of almost 13 years at Infinity, John had the unique opportunity to play a critical role in the genesis and evolution of the company's science, technology, and business. John, who has proven to be a sucker for worthy charities, once allowed his coworker to shave his head with a Flowbee to raise money for a local nonprofit organization focused on cancer patient support.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

No bio available.

• AI for Oncology, Precision Medicine & Health
• Data Science & Analytics Technologies

Dr. Andy Kilianski joined ARPA-H in May 2023 from the International AIDS Vaccine Initiative (IAVI), where he served as senior director for emerging infectious diseases. During this time, he led IAVI’s filovirus vaccine portfolio – including vaccines focused on Marburg virus and Sudan virus – while also supporting strategy development and key stakeholder engagement across the entire emerging infectious diseases portfolio. Before joining IAVI, Kilianski was a senior scientist and Science and Technology manager at the Department of Defense, where he built programs focused on countering emerging biological threats. During the onset of the COVID-19 pandemic, Kilianski led interdisciplinary teams on the Department of Defense COVID-19 Task Force, which focused on vaccine development, supply chain resilience, and COVID-19 operational data tracking and management. Kilianski received his doctorate in microbiology and immunology from Loyola University of Chicago, where he studied virus-host interactions important for coronavirus pathogenesis.

• AI for Oncology, Precision Medicine & Health
• Data Science & Analytics Technologies

As a seasoned software developer and technical leader, I excel at transforming complex challenges into intuitive, user-centric solutions. With a strong emphasis on product sense, I bridge the gap between intricate technical requirements and seamless user experiences, ensuring that sophisticated technologies deliver tangible value to end-users. Throughout my career, I have led diverse projects that required innovative problem-solving and strategic vision, consistently delivering high-quality software that meets and exceeds stakeholder expectations. I am passionate about collaborating with cross-functional teams to drive product development from concept to completion, optimizing processes, and fostering innovation at every stage. I thrive in dynamic environments where I can leverage my technical expertise and product-focused approach to create impactful solutions that address real-world problems and advance organizational goals.

• Software Applications & Services

Kiran Kodali is a value-driven data and digital transformation leader, currently leading the R&D Data Strategy and Governance at Sanofi (Pharma / Life Sciences). Kiran has had the opportunity to work across industries - including investment banking, US military and business aviation - with a focus on enabling business objectives from a data and digital standpoint. He has expertise in building and scaling capabilities across functions, that allow monetization on the data generated/acquired, to support decision making and improve business outcomes along the value chain.

• Data Management

Dynamic technical leader, pioneering at the intersection of AI, cloud architecture, and life sciences. 15+ years leading the development of sophisticated cloud-based infrastructures that serve as the backbone for critical data analytics in precision medicine and biotech. Shaped by the discipline of Brazilian jiu-jitsu, passionate about performance, adaptability, and strategic foresight.

• Data Platforms & Storage Infrastructure

Sri Krishnamurthy is a technology leader and life sciences expert, specializing in clinical systems and commercial operations. As Associate Director of Global Delivery & Operations at Regeneron, he supports GD-IT domains like Biostatistical Data Management, Early Clinical Development, and Clinical Sciences. Sri leads impactful projects such as digitizing clinical trial protocols, implementing advanced human sample tracking systems, developing a Scientific Data Lake, and enhancing analytical platforms with SAS, R, and Databricks. His work advances Regeneron's operational capabilities and scientific endeavors.

• Data Platforms & Storage Infrastructure
• Digitalization of Clinical Development

No bio available.

• AI for Drug Discovery & Development

Steven Labkoff is one of the leading clinician-informaticians in the US today, with 30 years of experience in the life sciences and healthcare sector. He has deep expertise in generating, managing, and analyzing data to accelerate drug development, personalized patient care, and improve medical outcomes. He is a collaborating scientist at the Department of Clinical Informatics at the Beth Israel Deaconess Medical Center. He serves as Global Head of Clinical and Healthcare Informatics, assisting life science clients in developing and implementing innovative informatics solutions throughout the entire drug development lifecycle. In addition, he will be working with foundations and not-for-profit groups in helping with data acquisition, management, and analytics to help these organizations meet their long-term goals. In addition, Steve is a collaborating scientist at the Beth Israel Deaconess Medical Centers Department of Clinical Informatics. Previously, Steve was Chief Data Officer for the Multiple Myeloma Research Foundation, the largest non-profit in the world focused on accelerating a cure for multiple myeloma. In that role, he architected, built, and ran the largest multi-data registry in oncology for multiple myeloma, enabling patients, clinicians, and researchers to combine multiple types of data (real-world data, genomics, and immunologics) to better understand their disease and subsequently to find more personalized treatments. His life sciences career includes leadership positions at Pfizer, AstraZeneca, and Deloitte Consulting. He also was Vice President of Life Sciences for Intelligent Medical Objects, a medical ontology and vocabulary company. While there, he prototyped and architected new applications to re-encoding clinical data with concept codes which resulted in a patent for identifying patients for clinical trials by using clinical concept codes. In addition, Steve is a fellow in at the American College of Medical Informatics, the American College of Physicians (ACP), and the American Medical Informatics Association (AMIA).

• Digitalization of Clinical Development

Dr. Mary Jo Lamberti manages multi-sponsored and grant-funded research projects at Tufts CSDD. She has extensive experience conducting market research on pharmaceutical industry practices and trends affecting contract research organizations and investigative sites. She has been a speaker at conferences and has published articles in trade and peer-reviewed journals. Prior to joining Tufts CSDD, Dr. Lamberti was Director of Market Research at CenterWatch. She has also worked on federally funded research studies in science education reform. Dr. Lamberti holds a B.A. from Wellesley College and a Ph.D. in Psychology from Boston University.

• Digitalization of Clinical Development

I have extensive experience as an enterprise leader in analytics and data strategy, with expertise in science, technology, and business. I have leveraged my capabilities to enhance R&D organizations' analytics, technology, and operations to accelerate innovation in pharmaceutical, biotech, academic, and government institutions. My work in analytics has driven operational efficiencies in drug discovery, laboratory operations, and supply chain management through web-based informatics, data analysis, visualization, and predictive modeling. My passion for innovation and data science spans areas like strategic planning, enterprise data science, business transformation, and global cross-functional team leadership. As a sought-after advisor to CEOs of both established organizations and startups, I have a proven track record in M&A integration and the establishment of new facility operations. Mentorship and coaching of professionals at all levels has also been a priority, along with community involvement that includes founding initiatives such as "Masks for Heroes" during the pandemic and establishing a leadership academy in Ghana. Recent work partially funded by the MIT Sandbox Innovation Fund includes MyCareerCompass and Career Office, which bring technology, data, and analytics (including AI/ML) to help people with their career development, career management, and job-seeking.

• Data Science & Analytics Technologies

Luis Lebolo is the Director of Software Engineering at Generate Biomedicines, with over a decade of experience in building innovative software solutions for the life sciences. He holds a Ph.D. in Particle Physics from Florida International University and has led the development of cloud-based platforms that support machine learning, data analysis, and scientific lab workflows. Throughout his career, Luis has designed and implemented large-scale informatics systems, from biomarker LIMS to pharmacogenomic platforms, helping scientists streamline complex workflows and improve data management. Fluent in both English and Spanish, he is passionate about leveraging cutting-edge technologies to drive scientific discovery and operational efficiency.

• Digital Biopharma

Steve is a "startup midwife" who has spent the last decade helping inventors turn their discoveries into businesses, whether in a startup, a university, or even a refugee camp. He most recently led the George Shultz Innovation Fund at UChicago, where he nucleated and invested in University spinouts. Prior to UChicago he was an Associate for Ocean Tomo's Innovation Management practice, where he advised companies on how to acquire, develop, and commercialize technologies.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Alex Li is a director of Janssen R&D Data Science, embracing this role since July 2020. His journey began with a profound 18-year chapter at GSK, where he contributed extensively across diverse domains, including bioinformatics, discovery, and clinical research. Since joining Janssen, Alex has been dedicated to pioneering data science solutions that drive advancements in precision medicine and innovative clinical trial design.

• Digitalization of Clinical Development

Xiaofeng Li joined Abbott/AbbVie in 2000. She is currently part of the Data Analytics and Visualization team within AbbVie Business Technology Solutions organization. Her team collaborates closely with scientists to develop tools aimed to enhance work efficiency. Xiaofeng possesses scientific expertise across various domains, including chemistry, bioassay, DMPK, safety science, and data science. She empowers research scientists to explore and derive valuable insights from previously disparate knowledge and data sources. Xiaofeng enjoys connecting with others who support the use of data to generate insights. Xiaofeng holds a MS degree in Chemistry from Wake Forest University.

• Software Applications & Services

Michael N. Liebman, PhD (theoretical chemistry and protein crystallography) is Managing Director of IPQ Analytics, LLC and CSO of United Cancer Centers after serving as Executive Director of the Chan Soon-Shiong Institute for Molecular Medicine. He is Adjunct Professor of Pharmacology and Physiology, Drexel College of Medicine and Adjunct Professor of Drug Discovery, Wenzhou Medical University and Fudan University. He serves on the Advisory Board for the Center of Biomedical and Health Research, University of Massachusetts (Lowell). Previously, he was Director, Computational Biology and Biomedical Informatics, University of Pennsylvania Cancer Center. He served as Global Head of Computational Genomics, Roche. He serves on the Board of the Nathaniel Adamczyk Foundation in Pediatric ARDS. Michael chairs Translational Medicine for the PhRMA Foundation and serves on the IUPAC Division on Human Health. His research focuses on computational models of disease that stress complexities of real-world patients and real-world clinical practice utilizing systems-based approaches for representation and analysis for pharma and healthcare.

• Bioinformatics
• Knowledge Graphs

Leonard Lipovich earned his B.A. (cum laude) in Genetics and Development from Cornell University (1998), and his Ph.D. in Genome Sciences from the University of Washington, Seattle (2003). He completed postdoctoral training at the Genome Institute of Singapore, where he discovered the first mammalian lncRNA functional in stem cell pluripotency and discovered the prevalence of primate-specific lncRNAs in sense-antisense gene pairs. Dr. Lipovich joined Wayne State University in Detroit, Michigan, USA in 2007, as an assistant professor, attaining an associate professorship and tenure in 2013 and a full professorship in 2019. In 2020, he transitioned to the Mohammed Bin Rashid University of Medicine and Health Sciences in Dubai, UAE. In 2014, Dr. Lipovich received the U.S. National Institutes of Health (NIH) Director's New Innovator Award. In 2015, he chaired both the Keystone Symposium and the Royal Society meeting on lncRNA. To date, Dr. Lipovich (h-index: 44) has published 86 peer-reviewed papers, delivered over 50 talks, and chaired numerous sessions and workshops at key conferences. His goal is to improve human health through personalized, lncRNA-targeted post-genomic therapeutics.

• AI for Drug Discovery & Development

Ankit Lodha is the Director of Data Science Portfolio Management at Janssen Research & Development. In his role, Ankit leads the data tokenization capability, a first-in-industry innovation project to link clinical trial data with real-world data (RWD) via tokenization. It enables real-world effectiveness studies and long-term follow-up (LTFU) to allow groundbreaking real-world evidence generation prior to licensure. In this role, Ankit executes various AI/ML models in supporting the execution of clinical trial portfolios. He worked on the COVID-19 vaccine program to build a data-driven COVID-19 Vaccine Development approach for Janssen. He operationalized it across multiple high-priority areas to ensure Janssen R&D continues to deliver on transformational medicines for patients. These include building new capabilities such as creating best-in-class R&D data science platforms and datasets by selecting the highest priority questions to pursue and systematically deploying Data Science capabilities while being a key catalyst in forming strategic external partnerships to accelerate ongoing efforts. Ankit has more than 10 years of global healthcare experience in pharmaceutical, biotechnology, and business. Prior to joining Janssen, he was a Team Lead at Takeda where he has led and executed multiple strategic initiatives across research, CRO management, clinical development, mergers and acquisitions, and operations. Preceding this role, he was working at Amgen in their clinical systems & analytics organization within R&D, areas of focus included portfolio governance and decision-making, R&D operating model optimization (including both clinical development and operations), external innovation, and Digital Health. Ankit received a Bachelor’s in Biotechnology Engineering from Dr. D.Y. Patil University, a Master’s in Business of Bioscience from Keck Graduate Institute, and an MBA from the University of Redlands – School of Business. He is the recipient of EB-1A status i.e., Alien of Extraordinary Ability (aka Einstein visa) in the field of Clinical Trial Analytics from the U.S. government (USCIS). This honor is awarded to less than 1% of professionals globally who have risen to the very top of their endeavor and brought major significance to their field at the national and international level.

• Digitalization of Clinical Development

Rana Lonnen is a healthcare technology investor, entrepreneur, and molecular biologist. At Novartis, she leads strategic investments in technology companies, on a mission to transform the healthcare ecosystem and make positive impact on people’s lives. Previously, Rana was Head of Preclinical Development at a UK biotech, Auspherix; investment consultant to IP Group in London; Founder and CSO of a UK-based Biotech, Axendos therapeutics. Prior to this, she was a Wellcome Trust-backed principal investigator in drug discovery in the field of Infection, Immunity, and Inflammation, author and inventor on high impact peer-reviewed publications and patents; before this, Rana worked at Bristol-Myers Squibb, in sales and marketing. Rana holds a PhD in molecular biology and an MBA from Imperial College London. She personally cares about equitable healthcare, social justice, sustainability, and the future of antimicrobial resistance. In her downtime, Rana likes to make culinary experiments, be in nature, and read. Rana is a board observer at Aktana, Cota Healthcare, H1 Insights, Koneksa, Mekonos, NuvoAir, and Dopavision. She is based out of Basel, Switzerland.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Industry experience includes 10 years to Vertex, 9 years at Bayer and 8 years at Schering-Plough as a medicinal chemistry lab head, project leader, and specialist in new drug discovery technologies. Freelance writer on science and pharmaceutical topics, with columns and articles appearing in Chemistry World, Contract Pharma, Pharmaceutical Executive, Genome Technology, and other publications. Author of the widely-read industry science and industry web site "In the Pipeline" (https://www.science.org/blogs/pipeline), quoted in Forbes, Fortune, the Wall Street Journal, etc. Specialties: Drug discovery research experience in oncology, metabolic disease, Alzheimer's, infectious disease and other therapeutic areas. Target experience in kinases, proteases, GPCRs, ion channels, nuclear receptors, and many additional categories.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Christina Lu is an accomplished informatics leader with a track record of building organizations that deliver complex informatics solutions and data platforms to advance scientific capabilities. She has more than 20 years of experience in the Biotech and Pharmaceutical industries. At Genentech, she leads a global organization of data and scientific experts within the Data Strategy and Delivery (DSD) organization in Product Development (PD) to deliver high quality multi-modal data assets that can inform portfolio and scientific decisions. Prior to her current role, Christina was the the Executive Director and Head of Data Management and Engineering within gRED Developmental Sciences organization, where she built a high-performing team that developed industry-leading data management and curation practices. They also delivered reusable and interoperable informatics systems, servicing numerous business and data needs in Development Sciences and Translational Sciences. She was also previously at Roche Palo Alto, Exelixis and Novartis. Christina received her M.S. in Biomedical Informatics from Stanford University. She also has a M.S. in Immunology and B.S. in Biochemistry/Cell Biology from UC San Diego.

• Pharmaceutical R&D Informatics

Enterprise and Solutions Architect at the Emerging Technologies Division at the National Labs (MITRE) with accomplished career in a variety of industries. Much of his work centers on medical research and national defense domains. As a skilled researcher/engineer, Ray has demonstrated the ability to architect, build, and mentor others in converting complex systems into simple component-based solutions. Ray’s current interest is in high-performance, agile Graph Databases/Analytics, Machine Learning, and Distributed systems.

• Knowledge Graphs

Christopher Lundy is a pioneering leader in enterprise architecture, AI, and quantum computing, with over 20 years of experience transforming digital strategies in biotechnology, pharmaceuticals, healthcare, life sciences, advanced research, and several other industries. At Pfizer, he led the development of innovative AI and quantum applications, including a Large Language Model for drug discovery and a virtual environment that accelerates R&D by simulating treatments. As founder of FindInfinite Labs, he explores quantum theory and AI-driven simulations to advance quantum computing proliferation and develop cutting-edge solutions. A frequent industry speaker, Christopher’s expertise in AI and quantum is helping to shape the future of biopharma innovation and scientific discovery.

• AI for Drug Discovery & Development

Dr. Lynch has over 25 years’ experience in Data science & Informatics in various start-ups and biopharma. He is interested in making data more accessible for better analysis, and established Curlew Research in 2014, working with pharma/biotech and life science informatics/data science companies.

• W1: FAIRification Lab—Applying FAIR Principles to Enhance Data Stewardship

As Principal Data Scientist at Moderna Eric leads the Data Science and Artificial Intelligence (Research) team to accelerate science to the speed of thought. Prior to Moderna, he was at the Novartis Institutes for Biomedical Research conducting biomedical data science research with a focus on using Bayesian statistical methods in the service of discovering medicines for patients. Prior to Novartis, he was an Insight Health Data Fellow in the summer of 2017 and defended his doctoral thesis in the Department of Biological Engineering at MIT in the spring of 2017. Eric is also an open-source software developer and has led the development of pyjanitor, a clean API for cleaning data in Python, and nxviz, a visualization package for NetworkX. He is also on the core developer team of NetworkX and PyMC. In addition, he gives back to the community through code contributions, blogging, teaching, and writing. His personal life motto is found in the Gospel of Luke 12:48.

• Digital Biopharma

Dr. Subha Madhavan is a dynamic and results-driven leader with a strong track record of excellence in organizations that operate in the nexus of science, technology and business. She is a world-class leader in AÍ/ML, Drug R&D, Precision Medicine, Digital Health, Data Science & Analytics, Bioinformatics, Product development, Clinical informatics and Health IT. She and her team were responsible for initiation, design and execution of several large national and international clinical research programs including Cancer Moonshot, TCGA, CPTAC and Human Cell Atlas. In her role as the Founding Director of the Innovation Center for Biomedical Informatics at Georgetown, she developed a workforce of over 25 employees, to include staff scientists, health IT, and operations personnel with full P&L responsibility for the business center and its R&D team. She has initiated and successfully directed several productive research and development programs at the Lombardi Comprehensive Cancer Center, MedStar hospital network, FDA, NCI and industry. She was co-leader of the FDA Center for Excellence in Regulatory Science at Georgetown and worked with the Oncology Center for Excellence, Vaccines and related biological products, and Office of the Chief Scientist. As an industry advisor, she advices biopharma, federal, academic clients develop organization-wide R&D, data science and digital health strategy.

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Cloud for AI/ML & Modern Data Science
• Knowledge Graphs
• Data Science & Analytics Technologies
• Generative AI Tools
• Pharmaceutical R&D Informatics
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management
• Digital Biopharma
• Digitalization of Clinical Development

Dr. Amrik Mahal currently serves as the Global Head of Information Technology for Research at AstraZeneca. In this capacity, he is responsible for shaping the IT strategy, collaborating with R&D senior leaders, and overseeing the delivery of all IT projects, services, and capabilities.

• Data Management

I hold a PhD in biochemistry, molecular, and structural biology from UCLA. My research background is in information theory, machine learning applications for single-cell biology, and mechanistic modeling. As a Biological Data Scientist at Tessel Bio, my current focus is on improving target discovery by developing new methods to model and explore tissue function in vitro.

• AI for Drug Discovery & Development

Brian joined AbbVie in 2018 as the head of the newly formed RAIDERS team within Research & Development’s Information Research division, focused on accelerating, scaling, and amplifying the work of AbbVie’s R&D community using Artificial Intelligence technologies like machine learning, deep learning, graph computation, and cognitive computing. Brian is a part of the leadership team building and directing the AbbVie R&D Convergence Hub (ARCH) as part of the R&D Convergence initiative and a member of the ACOS Scientific Innovation Council. Brian came to AbbVie after spending five years in technology consulting across many industries, and over a decade of additional experience before that working in trading and financial markets technology. During his consulting time, Brian was the architect of the United States’ Common Securitization Platform and the technology founder of Publicis.Sapient’s AI practice. While his primary focus is AI technologies, he was also a co-founder of the QuPharm quantum computing community and the Pistoia/QED-C Quantum Community of Interest. He is a frequent presenter at conferences on topics as diverse as optical networking, quantum computing, blockchain, cognitive architecture, and other emerging technologies that are all part of digital transformation. Brian holds a B.S. degree in Computer and Cognitive Science from Alma College and a M.S in Computer Science from the University of Chicago. He is a board member for the Chicago Innovative Executives League and for the Mundelein High School Business Incubator program. He has been involved with the Creative Destruction Lab at the University of Toronto’s Rotman School and as a panelist/reviewer for the National Science Foundation Secure and Trusted Cyberspace grant division. Brian lives in Lake Bluff, Illinois with his wife and four children.

• Knowledge Graphs
• Generative AI Tools
• Pharmaceutical R&D Informatics

A globally oriented technology executive leading research, biotech, and consumer products organizations through complex changes. I have built organizations for explosive growth, consolidated them in business downturns, and led merger/acquisition/divestiture programs. I have led teams in 20+ countries, led all aspects of IT including major business transformations and culture change across organizations. I am an adept strategic thinker with experience advising several early stage biotech firms, an advisory board member to a software startup, and board chair for large ($100M+) social services agency. I have set technology strategy, implemented global programs, fixed broken operating models, rebuilt teams, negotiated large scale partnerships, and always focused on business success.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Janice McCallum is managing director of Health Content Advisors. She is a respected analyst in the economics of publishing and has been actively involved in creating and marketing information products for over twenty-five years. She has held senior-level product management and content development positions in pioneering information companies, including Individual, Inc. (now part of Acquire Media), Dialog Information Services (now part of ProQuest), and DeepCanyon, a Hewlett-Packard company. After receiving her MBA from the Booth School at the University of Chicago, she began her career in online publishing at Dialog where she managed several financial and business database product lines and was responsible for licensing content from dozens of publishers. Janice expanded her content development and licensing expertise into healthcare, life sciences, market research, and news information products at both Individual, Inc. and Hewlett-Packard’s DeepCanyon and has leveraged that experience in her consulting practice. Clients have ranged from major publishing firms, including Thomson Reuters, Elsevier, D&B, McGraw-Hill, Hewlett-Packard, Microsoft, to scores of many smaller publishing, technology firms, and private equity firms. Janice is a frequent speaker at industry conferences on topics from Big Data in Scholarly Publishing to business models for data content. She was on the board of trustees at the Journal of Bone & Joint Surgery from 2014 through 2022 and led the Strategy Committee for JBJS.

• Knowledge Graphs

Proven C-level leader with deep experience running global Fortune 500, start-up, and emerging pharmaceutical businesses, possessing the unique ability to blend, build, and strengthen performance from the ground up. Broad understanding of market strategy development within clinically diverse programs that achieve meaningful product differentiation. Significant accomplishments creating profitable business development and investment community partnerships within the C-suite. Strategy/Vision: Deep start-up, transaction and capital raising success through the establishment and guidance of Adiso, Adastra, and Churchill; creation and execution of clinical development and business strategy to lead the companies from formation; with the identification and advancement of multiple first-in-class drug product assets; negotiated and managed lucrative business development partnerships; business development and licensing with Baxalta, transaction to Cothera Bioscience and Sun Pharma FZE. Change Leadership: Adaptable and insightful leader instrumental in the cultural and team transformation of Onconova from a private 16-person medicinal chemistry company into a commercially prepared 67-employee Nasdaq listed company executing a successful Initial Public Offering (IPO). Commercial Innovation: Directly involved in numerous successful product development/co-development programs and commercial launches within oncology and specialty therapeutics. Demonstrated ability to employ unique approaches to value pricing and contracting within competitive markets. Execution/Implementation: Ability to visualize and articulate both long-term and near-term goals while promoting excellence through organization design, leverage of key functional areas, with clear decision making and process application. Global M&A: Marshalled Churchill Pharma through nine-month transaction process and successful sale of assets prior to product approval by FDA, while simultaneously preparing for a Churchill launch. While at Onconova, initiated and negotiated two separate license agreements for Japan/Korea and Europe

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Ophelia Mok is the Senior Manager of Business Analytics at the Global Development Office in Takeda Pharmaceuticals. With a background in Epidemiology and Biomedical Engineering, Ophelia has a unique perspective on the intersection of healthcare and technology. Prior to joining Takeda, she worked on Clinical Analytics Strategies at Anthem and a healthcare AI startup, AllazoHealth, based in New York City. Ophelia is passionate about leveraging data and technology to improve patient outcomes.

• Digitalization of Clinical Development

10 years research experience in Molecular Neurogenetics and Circuits Neuroscience with broad domain knowledge in experimental neuroscience and analysis of molecular, imaging, electrophysiology, and behavioral data. 5 years experience in preclinical drug discovery informatics, advancing research workflows automation development, and FAIR In-vivo data management from within different roles: Business Analyst, Developer, and Product Owner (PSPO certified)

• W4: Making Data AI-Ready

Douaa Mugahid is currently a research scientist and faculty member at the Harvard TH Chan School of Public Health which she joined after the COVID19 pandemic revealed the importance of better digital infrastructure, more interdisciplinary research, and public-private partnerships for local and global pandemic preparedness. In her current role, she manages multi-modal data for a large NIH-funded consortium of international researchers focused on identifying principled vaccine strategies for adults at risk of TB – the world’s deadliest infectious disease by number of lives claimed. She also manages a partnership with Siemens Healthineers focused on using digitally-connected diagnostics for public health monitoring. Finally, she is a part-time Senior Consultant at the Brussels-based boutique consulting firm myEUconsulting, where she helps high-risk but promising early-stage Biotech/Techbio/Digital Health startups obtain EU funding.

• Digital Biopharma

No bio available.

• Generative AI Tools

Srivatsan has over thirty years of experience in growing businesses in the Digital, Data, AI, Analytics, IT, Product and Operations management areas across several industry verticals. Currently he is helping companies unlock exponential growth opportunities to scale their businesses by leveraging the power of AI. Previously as Chief Digital Officer for R&DS Technologies, IQVIA he was responsible for driving growth and leading product development and operations of R&DS Technologies. Prior to that, as Chief Growth Officer for EXL he oversaw the Sales & Marketing, Consulting and Strategy functions helping EXL become a Strategic digital transformation partner to its customers. Before that, as Venture partner, he grew Cognizant’s foray into Digital & Platforms. He identified, incubated and grew innovative digitally enabled ventures across the Healthcare & Life Sciences value chain. Early on, He was responsible for growing Cognizant’s Life Sciences business unit to be a Tier one provider. He has worked with the many of the top 50 global Life Sciences organizations providing them comprehensive end-to-end consulting, analytics, business process and IT solutions. He has provided strategic leadership in helping life sciences organizations leverage technology and the global delivery model to effectively transform their businesses. Srivatsan was recognized as the top 100 most inspiring people in the life sciences industry award by PharmaVOICE publication in 2010 and 2021. Srivatsan holds a bachelor's in electrical engineering from B.I.T.S. in India and a master's degree in electrical engineering & computer science from Northwestern University.

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Pharmaceutical R&D Informatics
• Digitalization of Clinical Development

Radhesh Nair focuses on democratizing access to clinical data and creating analytics-driven pan-R&D insights and solutions.

• Pharmaceutical R&D Informatics

Kimberly A. Nearing, M.S., is a Venture Partner at BVCF Management, leading U.S. investing activities including deal origination, execution, fundraising, investor relations, and portfolio management. Additionally, as Chief Business Officer for three biotech companies, she oversees business development, capital raising, and IPO campaigns, and serves as a board member for MaveriX Oncology and the RV Foundation in Washington, D.C. Kimberly has 20 years of international financial services experience in venture capital and investment banking, coupled with substantial life sciences and health tech domain experience in startups and public companies. She began her career at Amgen in BD and marketing, where she served on two product launch teams, and held an executive position at IBM Healthcare where she was elected to a 20-person team charged with developing IBM’s global healthcare strategy. Her career highlight is her global network, particularly in the U.S., Asia, and the Middle East, and cross-border deal-making experience. Her educational background includes an MSc with Honors from Harvard University, a BA in Economics with Distinction from the University of Michigan, and certificates in Healthcare AI/ML from Stanford University and Generative AI: Prompt Engineering from IBM.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Creating and embedding the User Experience and Business Analysis strategy within Novartis Biomedical Research, informing our scientific products and software solution. Leading a global team of UX research, design, and business analysis professionals. We enable the development of scientific products that solve real underlying problems and address user needs by applying a set of qualitative and quantitative research methods. More than 15 years of professional experience in Life Sciences in various domains such as User Experience, Agile methodologies, Project Management, Business Analysis, Leadership & Management, Software Development.

• Software Applications & Services

Giovanni Nisato is a Pistoia Alliance Associate where he currently manages the FAIR implementation project. Giovanni works as a consultant for bio-pharmaceutical organizations, innovation networks and digital health start-ups. He has 25 years’ experience in collaborative innovations in international settings across diverse industries. Affiliate professor at the Grenoble School of Management’s Biopharma Program, Giovanni holds a PhD in physics and is a certified Project Management Professional (PMP/PMI).

• W4: Making Data AI-Ready
• W1: FAIRification Lab—Applying FAIR Principles to Enhance Data Stewardship

Steve is a software engineer with a background in cloud infrastructure and data systems. He graduated from the University of Connecticut with a degree in Computer Science and a minor in Mathematics. He has a breadth of experience across renewable energy, aquatics research instrumentation, and professional services. In his last role, Steve worked in consulting as a specialist in data warehousing where he designed complex analytics platforms using cutting-edge cloud infrastructure. For the past 4 years, he has worked at Dyno Therapeutics where he helped scale the company from 30 people to over 100 by driving the technical architecture and hiring top talent. Outside of technology, Steve can often be found outside getting his adrenaline up by snowboarding, rock climbing, or mountain biking.

• Data Platforms & Storage Infrastructure

Patrick O'Mara is an accomplished leader in Information Technology and Biotechnology, currently serving as the Associate Director of Research Informatics at Photys Therapeutics. With over 15 years of experience, he has a proven track record in developing strategic IT initiatives that drive digital transformation and enhance scientific workflows. His recent endeavors focus on architecting a cutting-edge informatics ecosystem that supports scientific research. Previously, he led a global team and played a pivotal role in aligning IT strategies with organizational goals while ensuring operational efficiency. A passionate advocate for continuous improvement, Patrick actively engages with industry peers, sharing insights at conferences and contributing to publications on innovative solutions for the biotech sector. Patrick holds a Master’s in Bioinformatics from Harvard Extension School.

• Cloud for AI/ML & Modern Data Science

International marketing and business development professional with proven strategic agility and executional excellence across a broad range of therapy areas and geographies. Strong leadership and change management expertise is combined with 1st class project, alliance management, operational and entrepreneurial experience.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

I am passionate about translational research and clinical informatics, where my +10 years of experience in cancer research and +7 years of bioinformatics experience can be leveraged to accelerate the clinical application of scientific knowledge. My main research goal is to facilitate public data reuse and develop user-friendly bioinformatics software. I have expertise in: - Cancer Genomics - Software Development - R/Bioconductor - Cloud Computing - Docker - Molecular and Cellular Biology laboratory technologies - DNA repair and immune deficiency - Gene targeting/ editing

• Data Management

Steve Pagliuca is the Chair, CEO and Founder of PagsGroup, an investment firm focused on high growth companies in tech, biotech, healthcare and the sports industry. He has played a leading role in investing in prominent tech, media, telecom and financial services businesses. PagsGroup was recently announced as a lead investor in Liquid AI, a pioneering liquid neural network technology company. In 2016, the Pagliuca Family Foundation helped create the Pagliuca Harvard Life Lab. With a focus on biotech and life sciences, the lab teams have raised $1.16 billion and incubated 59 companies. In addition, Pagliuca is the co-founder and executive chair of Arena BioWorks, a privately funded, fully independent biomedical institute. Pagliuca is a co-owner and managing partner of the Boston Celtics, president of the Shamrock Foundation and serves on the NBA Board of Governors. He is also a co-owner and co-chair of Atalanta Bergamasca Calcio, a professional football club based in Italy. Mr. Pagliuca received a B.A. from Duke University and an M.B.A. from the Harvard Business School.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Irene is a passionate leader in data science, digital technologies, visual analytics, machine learning, and artificial intelligence. With extensive experience in the pharmaceutical industry and deep domain knowledge in R&D, Irene has successfully translated complex scientific needs into actionable IT projects with a 100% success rate. Known for a unique blend of technical expertise and soft skills, Irene has led teams to develop and deliver value-added digital solutions that drive innovation and efficiency. An inquisitive individual at heart, Irene continually seeks to leverage cutting-edge technologies to solve real-world challenges in healthcare and beyond.

• Generative AI

Abhishek leads a global machine learning team in AbbVie that deals with most of machine learning that happens in drug discovery at AbbVie. We are responsible from early discovery (target) to late discovery leading up to pre-clinical work. Broadly have team in machine learning in chemistry, machine learning in imaging/multiomics, machine learning in genomics, and machine learning advisor for AbbVie-calico alliance. In his previous life, Abhishek was founding member of machine learning team in imaging at Tempus Labs, working in field of precision medicine.

• Generative AI

A scientific leader with 10+ years of experience driving breakthrough innovations in condensate biology and drug discovery. Leading big data-driven research to transform pioneering ideas into successful drug discovery programs and partnerships. Expert in condensate biology, with groundbreaking discoveries in top journals. Skilled in leading multi-disciplinary teams and managing global collaborations to deliver high-impact results in fast-paced settings. Passionate about advancing healthcare by integrating innovative biology and AI/ML.

• Knowledge Graphs

No bio available.

• Cloud for AI/ML & Modern Data Science
• Data Science & Analytics Technologies
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management

Dr. Plasterer has pursued interests in bioinformatics, clinical informatics, systems biology and biomarker discovery over the last twenty years in both industry and academia. He co-founded PanGenX (a Personalized Medicine/Pharmacogenetics Knowledge Base start-up), directed the project planning and data interpretation group at BG Medicine, and held an adjunct professor position in the department of Chemistry and Chemical Biology at Northeastern University. He now leads FAIR data and Knowledge Graph initiatives at AstraZeneca. In these roles at AstraZeneca, Dr. Plasterer has been responsible for establishing and executing the linked data strategy which includes knowledge representation, vocabulary & metadata services, semantic visualization, analytics and business case development. This strategy has been deployed to build the competitive intelligence and integrative informatics frameworks for R&D. Tom also serves on the Pistoia Alliance FAIR data implementation board.

• Knowledge Graphs
• Generative AI Tools
• Pharmaceutical R&D Informatics

Radesh is a seasoned Bioinformatician with 10+ years of experience in harnessing computational power to unravel biological complexities. With a strong foundation in genomics, bioinformatics tools, platforms, he possess expertise in Biological & Omics data mining & complex Bioinformatics analysis including Single-cell data analysis, visualization, Spatial Transcriptomics pipeline development.

Radesh has a proven track record of working on cutting-edge genome analysis - First in the world to sequence, assemble, annotate and publish the complex Lavender genome. He is passionate about developing novel Bioinformatics tools for analyzing the human genome, collaborating with interdisciplinary Biopharma teams and leveraging bioinformatics to drive scientific advancements and challenges.

• Bioinformatics

Yohann is the Sr. Director of Data Platform at Tessera Therapeutics, a genome engineering company that writes therapeutic messages into the genome to treat diseases at their source. He studied Biotechnology and Informatics in France followed by a PhD in Computational Chemistry at the University of Zurich, Switzerland. After graduating, Yohann joined PerkinElmer Informatics as a business analyst. He later joined Novartis in the Scientific Information Systems team followed by a position as head of data science at Voyager Therapeutics. Currently, as head of data engineering at Tessera, Yohann is focused on building a data platform to provide the computational environment to support the scientific team.

• Cloud for AI/ML & Modern Data Science

Allison Proffitt is a science writer with a background in biology and chemistry, research experience in cancer biology, and an expanding repertoire in biotech, AI, and battery chemistry. She serves as the editorial director for the Healthtech Publishing media group, a growing collection of online news sites. In addition to Bio-IT World, her work has been published by Nature Biotech, Chemical & Engineering News, and the Economist Intelligence Unit. She has a bachelor’s degree in communication of science, engineering, and technology from Vanderbilt University and a Master’s degree in science and medical writing from Johns Hopkins University.

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Cloud for AI/ML & Modern Data Science
• Data Science & Analytics Technologies
• Pharmaceutical R&D Informatics
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management
• Digitalization of Clinical Development

Yuri Quintana, Ph.D., is a global leader in developing and evaluating digital health systems. He is Chief of the Division of Clinical Informatics at Beth Israel Lahey Health and Assistant Professor of Medicine at Harvard Medical School, Harvard University. He leads the DCI Network (https://www.dcinetwork.org), which brings together national-level leaders to work on complex health problems requiring collaborations between institutions, government, and the private sector. His research is focused on learning networks and clinical care collaboration platforms that empower patients, families, and health professionals. He is developing InfoSAGE, a mobile app (https://infosagehealth.org) for medication and symptom management. He created Alicanto Cloud (https://www.alicantocloud.com), an online platform for learning and collaboration used by health professionals at Harvard-affiliated hospitals such as Beth Israel Deaconess Medical Cancer to disseminate best health care practices and virtual consultations. Alicanto is used at the Massachusetts Institute of Technology’s JWEL Center for sharing best practices in education. Alicanto has won numerous international awards. As a Senior Scientist at Homewood Research Institute in Canada, he has developed new methods to evaluate digital mental health systems using evidence-based approaches. Previously, at St. Jude Children’s Research Hospital, he envisioned, implemented, and managed global eHealth solutions for children with cancer that have improved the lives of countless children and made a significant contribution to global clinical informatics.

• Digitalization of Clinical Development

Brigitte Raumann is a Product Manager at Globus and led the effort to enable Globus support for management of protected research data, including PHI and CUI. As the Globus Privacy Officer, she continues to oversee the Globus compliance program and incident investigations. Brigitte has focused her career on providing researchers with the software tools and data they require to advance discovery. Her decades of experience span sectors as diverse as biotech, publishing, patent law, and academic clinical research. Brigitte Raumann earned her B.A. from the University of California, Berkeley and her Ph.D. in biochemistry from the Massachusetts Institute of Technology.

• Bioinformatics

Dr. Kamal Rawal is an interdisciplinary professional with extensive experience in machine learning and bioinformatics. He has successfully executed large-scale complex projects such as Semi-Automated Text Mining System, an AI-based Vaccine Discovery System; Next-Generation AI-based Cancer Diagnostic System, & AI-Driven Obesity and Diabetes Management System. Currently, he is working as a Project Director on an International project. Concurrently, he holds an Associate Professor position in one of the leading universities and mentors several AI-based startups.

• AI for Drug Discovery & Development

Christian Reich is founder and CSO of Nemesis Health, a company aimed at transforming cancer research through scalable and reliable Real-World Evidence. He is also Professor of the Practice at Northeastern University, where he supports the OHDSI Lab and the Real-World Master’s Program. Since its inception, he has served as Principal Investigator at OHDSI, a global Open-Source and Open-Science collaborative for comprehensive evidence about disease, healthcare delivery and the effects of medical interventions through large-scale analytics. Prior to that he was a Principal Investigator and Program Manager at the OMOP Program. Christian has more than 15 years of experience in life science research and medicine. He began his career as a practicing physician in Berlin and Ulm, Germany before transitioning to the European Bioinformatics Institute to work on the Human Genome Project. In 1988, he joined the biotech industry, where he worked in various positions in Biotech, Pharma and CROs on typical challenges in drug research and development, such as gene sequence and expression analysis, clinical trial design and analysis, systems biology, and outcome research, applying computational methods to large scale biological data. Christian received his bachelor’s degree in preclinical training from Humboldt University in Berlin and holds his M.D. and doctorate from the Medical University of Lübeck, Germany where he focused his research on T-cell activation and regulation.

• Digitalization of Clinical Development

Philippe Rocca-Serra graduated from the Ecole Nationale Supérieure d'Agronomie de Rennes, France with a Diplôme d'Ingénieur before completing a PhD in Molecular Genetics from the University of Bordeaux (2001), during which he was supported by EMBO fellowship supporting collaboration the University of Oslo. He then joined the EMBL European Bioinformatics Institute (EBI), contributing to the design and development of databases, tools, and data standards for communicating scientific results generated by Omics technologies. He joined the Oxford e-Research Centre in 2010 and has continued developing his activities on open data and open science.

• W1: FAIRification Lab—Applying FAIR Principles to Enhance Data Stewardship

I am a scientific and regulatory leader with expertise in all facets of scientific research, clinical trials, drug, therapy, vaccine, and medical device development and regulatory approval. With my broad knowledge and skills with the lab and clinical trial development and operations, I am able to effectively test cutting-edge novel medical products for infectious diseases, virology, microbiology, immunology, vaccinology, and oncology. I am also skilled in managing research projects, programs, functional areas, and Clinical Research Organizations (CROs). I have experience in directing cross-functional teams across multiple platforms while successfully accelerating the development and regulatory approval of innovative medical products and digital health technologies. I lead scientific affairs, clinical affairs, Qa/Qc, regulatory affairs, and policy development and implementation for the successful conduct of modern trials such as Decentralized Clinical Trials using innovative Digital Health Technologies. I am an a biomedical innovator, strategist, influencer and communicator who successfully leads organizations’ functional areas, programs and projects with P&L over $1B.

• Digitalization of Clinical Development

Robin Röhm is co-founder and CEO of Apheris, enabling governed, private, and secure access to life science data for ML. Robin is passionate about helping organizations safeguard their data assets and IP while ensuring it can be leveraged for AI. Having experienced first-hand the challenges of distributed data and regulatory constraints, he understands the need to overcome these to unleash the true value of life science data that’s currently sitting unused in organizations today. It’s this data that will ultimately help us transform drug discovery and development. Prior to Apheris, Robin founded a start-up in the Genomics space, worked in the financial industry, and has degrees in medicine, philosophy, and mathematics.

• Cloud for AI/ML & Modern Data Science

Dr. Mathew Rose is an Investor, Physician, Entrepreneur, and Blockchain Specialist focused on innovations that improve health and quality of life. He founded SAAVHA, a social impact start-up that personalized patient experiences to reduce inequity and administrative friction around patient consent. He currently serves as a Co-Chair for the IEEE-SA IC19-004-01 Clinical Trials Technology Modernization Network (CTTMN) and sits on the advisory board of several start-ups. Previously, Dr. Rose served as the Patient Identity Sub-committee lead for a PhUSE Blockchain in Clinical Trials initiative and has more than 15 years combined work in Clinical and Translational Medicine workflow. He has authored numerous peer-reviewed publications and spoken Internationally on Cybersecurity and Blockchain in Healthcare with mentions in Forbes, CoinDesk, and The Parallax. Dr. Rose holds a Medical Degree from the Royal College of Surgeons in Ireland, a Masters in Biotechnology from UPenn, a Masters in Physiology from Georgetown, and a Bachelors in Neuroscience and Business from the University of Pittsburgh.

• Digitalization of Clinical Development

Dr. Jeffrey Rosenfeld, PhD, MBA has extensive experience in genomics and bioinformatics. He is the author of over 40 scientific publications, a graduate-level textbook, and the recipient of a US patent. He received his undergraduate education at the University of Pennsylvania and his PhD in biology from NYU. He performed his doctoral research at the prestigious Cold Spring Harbor Laboratory. Over his 15-year career in genomics, he has worked on a wide range of biological and genetic projects including genetic association studies of schizophrenia, genomic testing of embryos for fertility treatments, gene patent litigation, and clinical cancer genome sequencing. For the past five years, he has been an Assistant Professor of Pathology and Laboratory Medicine and the head of the Bioinformatics Core at the Rutgers Cancer Institute. In this role, he has become very familiar with laboratory testing both for cancer and other genetic diseases. He has set up the computational infrastructure for multiple tumor sequencing panels as well as a clinical data warehouse. Dr. Rosenfeld is always at the leading edge of technology and is looking for the newest ideas that can be used for scientific research and diagnostics including single-cell techniques and long-read sequencing. Additionally, Dr. Rosenfeld has been sought out for his expertise as the head of Rosenfeld Consulting LLC. Clients come to him seeking advice regarding genomics, oncology, and laboratory testing. Due to his long tenure in the field and his knowledge of genomics as well as finance, he can give a clear assessment of the companies and their potential. Companies approach Dr. Rosenfeld looking for his expert-level genomics knowledge, industry insight, and management experience.

• AI for Oncology, Precision Medicine & Health
• Bioinformatics

Dr. Anthony Rowe is currently Head of Technology for the Global Scientific Capabilities at Janssen R&D Business Technology where he is responsible for the end to end digital strategy to enable the invention and development of Janssens therapeutic pipeline. He has previously had responsibility for Digital Health Technologies, Biomarker and Translation Informatics and External Innovation. Prior to joining Janssen he was a Director of Product Management & Founding Member of InforSense Ltd an innovative big data analytics company that provided Pharmaceutical, Financial Services and Telecommunication customers access to machine learning and high performance computing technology. During his tenure at Inforsense he had roles leading Engineering, Marketing, Technical Sales as well as Product Management and was involved in both fund raising, growing the company from 7 to 150 people and a successful exit of the company. Dr. Rowe holds a PhD in Computer Science and an MSc in Artificial Intelligence from Imperial College London and a BEng in Computer Systems Engineering from the University of Warwick.

• Pharmaceutical R&D Informatics

Tamerlan Adamovich Saidov, Ph.D, has 15 years of experience driving innovation in medical physics and the pharmaceutical industry. He has led numerous projects in drug product development, digital toxicology, digital transformation, and data strategy. Tamerlan is currently a CMC and Data Strategy Consultant at Zifo RnD Solutions, where he leads global digital transformation, advanced CMC-specific data strategy transitions, and data governance initiatives for top pharma companies. Tamerlan is passionate about applying a deep scientific approach, AI, and data-driven decision-making to enhance business processes and drug development in the complex CMC space.

• Digital Biopharma

I am interested in systems biology, the immune system, sequence analysis, and automation, omics methods such as single-cell RNAseq and Somascan, digital devices for clinical trials, and causal modeling of clinical and scientific data. At NIBR my group has developed web applications that track scientific workflows, automated data pipelines including external data sources, and developed a shared services layer that has been used for three subsequent applications. We have been internalizing and scalably deploying open-source software such as SPRING and cellxgene. AWS, Scala, Python, R, and Typescript are some of my favorite tech.

• Data Platforms & Storage Infrastructure

Since 2001, Susanna operates in the area of data interoperability, research integrity, and the evolution of scholarly publishing, working with and for researchers, service providers, journal publishers, library science experts, funders, and learned societies in the academic as well as in the commercial and governmental setting. With her Data Readiness Group (https://datareadiness.eng.ox.ac.uk), at the University of Oxford, she: (i) enables science by investigating and implementing methods, standards and tools to improve data curation and publication; (ii) influences data policies by leading and promoting guiding principles for data management and stewardship to support data reuse; (iii) prepares the new generation of scientists by creating and delivering educational material, to address the glaring lack of courses in these specialized subjects. An author of the FAIR Principles, Susanna has initiated and participated in a variety of community activities across disciplines, including: founder of the Nature's Scientific Data journal, member of several Boards of Directors (e.g. Dryad, Centre of Open Science) and formal standardization groups (e.g. ISO TC/276, EOSC FAIR Metrics and Data Quality Task Force). In the context of ELIXIR, she a co-lead of the ELIXIR Interoperability Platform (https://elixir-europe.org/platforms/interoperability).

• W1: FAIRification Lab—Applying FAIR Principles to Enhance Data Stewardship

Justin Scheer serves as the Vice President of In Silico Discovery. In this role, he oversees a global team delivering cutting-edge solutions in AIML, Bioinformatics, Cheminformatics, Structure-based Drug Design, Protein Modeling, and Generative Design. His modality expertise spans a wide spectrum, including Small Molecule Discovery, Peptides, Antibody Discovery/Engineering, Bispecifics, siRNA, Gene Therapy, Cell Therapy, and RNA platforms and his team impacts programs across all of J&J’s Therapeutic Areas. Justin holds a PhD in Biophysics and Biochemistry from Washington State University and an NIH Postdoctoral Fellowship at the University of California, San Francisco. Before becoming head of In Silico Discovery, he held the position of Vice President, Interim Head of Cell Therapy and Vice President, Gene Therapy and Gene Delivery Platforms. Prior to J&J, Justin was Executive Director for Boehringer Ingelheim’s Biotherapeutics Discovery & Engineering Platform Capabilities team, and earlier, led the discovery of multiple therapeutic molecules at Genentech, including Lunsumio, a bispecific antibody for lymphoma patients.

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Cloud for AI/ML & Modern Data Science
• Data Science & Analytics Technologies
• Pharmaceutical R&D Informatics
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management
• Digitalization of Clinical Development

Dr. Andreas Scherer is the CEO of Golden Helix. For over two decades, the company has delivered industry-leading bioinformatics solutions to advance life science research and translational medicine. Its innovative technologies and analytic services empower clinicians and scientists at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from next-generation sequencing and microarrays. With its solutions, hundreds of the world's hospitals, testing labs, academic research organizations, and governments can harness the full potential of genomics to identify the cause of disease, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in thousands of peer-reviewed publications. He is also the CEO and President of Salto Partners, a management consulting and investment firm in Nevada. He has extensive experience successfully managing growth and orchestrating complex turnaround situations. Dr. Scherer holds a PhD in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is the author and co-author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, "Be Fast Or Be Gone," was a prizewinner in the 2012 Eric Hoffer Book Awards competition and was named a finalist in the 2012 Next Generation Indie Book Awards!

• AI for Oncology, Precision Medicine & Health
• Bioinformatics

Sebastian Schlicker has more than 15 years of experience in managing pharma R&D IT projects, specializing in the implementation of global enterprise software solutions for large molecule R&D. As the director of Genedata’s Biologics business, Sebastian oversees all major consulting and deployment projects globally. Currently based in Basel, Switzerland, Sebastian previously worked out of the Genedata Boston office, where he helped to build Genedata’s biopharma business in the US. Among his many responsibilities, he led implementation and customization projects for major US biopharma companies. Before joining Genedata, Sebastian worked at Sanofi, where he managed the implementation of new R&D platforms in both small- and large-molecule R&D, covering the complete project life-cycle and resulting in integrated and harmonized enterprise solutions used by scientists around the globe. Sebastian holds a degree in Computer Science and Economics from the University of Applied Sciences in Darmstadt, Germany.

• Digital Biopharma

Weiwei Schultz leads the Multi-Omics Pipeline team within Data Science and Digital Health at Johnson & Johnson Innovative Medicine. Her team's goal is to harness advanced data science techniques to integrate and analyze multi-omic data, driving innovation in healthcare and improving patient outcomes. Her team is currently focusing on leveraging cutting-edge technologies to streamline data analysis and support personalized medicine initiatives.

• Data Science & Analytics Technologies

As an early pioneer of microarray technology, Doug authored some of the first publications describing experimental and computational approaches for large scale transcriptional analyses. After completing his Ph.D. in George Church’s lab at Harvard, he joined the Novartis Institutes for Biomedical Research where his 14-year career spanned the entire drug discovery pipeline, including significant work in target ID/validation, high throughput screening, and preclinical safety. In 2017, Doug founded Plex Research to develop a novel form of AI based on search engine algorithms. Plex’s unique platform has helped dozens of biotech and pharma companies accelerate their drug discovery pipelines by providing interpretable and actionable analyses of massive chemical biology and omics data sets.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Vimala has over 10 years of experience in Pharma and Research in various capacities. She is currently a Senior Principal Scientific Product Operations Manager, Drug Candidate Selection Product Line with the RX group at Novartis Institutes for Biomedical Research in Cambridge, MA. Vimala specializes in Pharmacy and Bioinformatics, focusing on managing and supporting scalable scientific small molecule data and software solutions within the biomedical and pharma industry. She has a proven track record of driving technology innovation, fostering strategic collaborations, and delivering impactful results. Her skills include scientific data management, optimizing visualization and reporting.

• Data Platforms & Storage Infrastructure

Vishakha Sharma is a Principal Data Scientist for diagnostic information solutions at Roche, where she leads advanced analytics initiatives such as natural language processing (NLP) and machine learning (ML) to discover key insights improving NAVIFY product portfolio, leading to better and more efficient patient care. Vishakha has authored 40+ peer-reviewed publications and proceedings and has given 15+ invited talks. She serves on the program committee of the ACM-W, NIPS, AMIA, and ACM-BCB. Her research work has been funded by the NIH Big Data to Knowledge (BD2K) initiative to build an NLP precision medicine software to automate molecular and clinical information extraction, categorization, and ranking of clinical evidence associated with biomarkers that predict response to cancer therapies. She holds a PhD in computer science.

• Generative AI Tools

No bio available.

• Digital Biopharma

Woody Sherman is CEO, Psivant Therapeutics and a thought leader in molecular simulations and computer-aided drug design, with over 90 peer-reviewed publications covering novel methods and applications. As Chief Computational Scientist at Roivant, Woody oversaw the computational strategy, implementation, and deployment of computational methods. He received his B.S. in Physical Chemistry from the University of California at Santa Barbara where he studied nonlinear optical properties of organic polymers using computational quantum mechanics methods. He completed his Ph.D. at MIT working in Professor Bruce Tidor’s lab where he examined the role of electrostatics in protein-ligand binding and implemented a novel method for optimizing ligand binding specificity across a panel of targets. While in graduate school he worked at Biogen where he developed novel methods to enhance antibody affinity via electrostatic charge optimization, resulting in a publication and patent. As Global Head of Applications Science at Schrödinger, led research, product development, methods development, and the deployment of Python-based tools. He also worked closely with Pharma partners on research projects and collaborations. Woody has published on a broad range of topics, including induced-fit docking, ensemble docking, molecular dynamics, free energy simulations, protein design, small molecule optimization, cheminformatics, hybrid ligand/structure-based methods, charge optimization, pharmacophore modeling, and more.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Chris joined Merck in 2023 as a product manager in the Data Movement and Storage product within MRL IT. In his role, he is responsible for Merck's global chromatography data systems and SDMS tools and leads the team who is implementing the enterprise data harmonization and standardization platforms and consumption pipelines for more efficient end-to-end workflows. After receiving his Ph.D. in Analytical Chemistry from Prof. Robert Synovec's group at the University of Washington in 2011, Chris worked for 12 years at Dow Chemical where he developed novel analytical chromatography solutions to support manufacturing and research and development needs and led a modernization of Dow R&D to a global Cloud-based CDS architecture.

• Pharmaceutical R&D Informatics

Dr. Sliz is a structural biologist with expertise in non-coding RNA regulation, an Associate Professor in Pediatrics and in Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Dr. Sliz has been leading research computing at Boston Children’s Hospital since 2016. Some of the BCH-wide programs developed under his leadership include Pediatric Scholar, Children’s Rare-Disease Cohorts genomic data initiative, bioinformatics and genomics consulting services, and a Longwood-wide CryoEM computing effort. Dr. Sliz also founded and leads SBGrid - a global structural bioinformatics consortium. He is affiliated with Manton Center for Orphan Disease Research.

• Bioinformatics

Claire is a partner at SpringTide and has spent her career focused at the intersection of healthcare, life sciences, and business. Prior to SpringTide, she was an investor at Meridian Street Capital, where she focused on seed-stage health tech, and Anterra Capital, where she focused on the intersection of biotech and agriculture while launching several animal health startups. Previously, she served as the Chief of Staff at Crestovo, a microbiome therapeutics startup acquired by Finch Therapeutics. She began her career at ClearView Healthcare Partners, a boutique life sciences consultancy, where she advised pharma and biotech clients on a variety of growth strategy topics. Claire holds bachelor’s degrees in biological engineering and management science from MIT. She is on the board of Leash Labs and serves as a board observer at IgniteData and Paterna Biosciences.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Dr. Christopher Southan works at the interface between bioinformatics, cheminformatics, pharmacology and drug discovery. His current role as Data Scientist at Medicines Discovery Catapult, UK (working remotely from Sweden) was preceded by being Principle Consultant at TW2 informatics in Göteborg, Sweden. In turn this was preceded by Senior Cheminformatian for the Edinburgh University BPS/IUPHAR Guide to Pharmacology database team 2013-18. Prior to this he set up TW2Informatics, engaging in patent data consulting for SureChem (2011-12) and the AstraZeneca Knowledge Engineering Program for testing and documenting Chemistry Connect (2009-11). During 2008-9, he coordinated the ELIXIR Database Provider Survey at the EBI, preceded by a Principle Scientist and Bioinformatics Team Leader position in AstraZeneca, Mölndal (2004-7) preceded by senior bioinformatics positions at Oxford Glycosciences Gemini Genomics and SmithKline Beecham. He has a PhD in Protein Chemistry from the Ludwig Maximillian University of Munich and a BSc Hons in Biochemistry from Dundee University (further information on LinkedIN).

• AI for Drug Discovery & Development

Parthiban Srinivasan, an experienced data scientist, earned his PhD from Indian Institute of Science, specializing in Computational Chemistry. After his PhD, he continued the research at NASA Ames Research Center (USA) and Weizmann Institute of Science (Israel). Then he worked at AstraZeneca in the area of Computer Aided Drug Design for Tuberculosis. Later, he headed informatics business units in Jubilant Biosys and then in GvkBio before he floated the company, Parthys Reverse Informatics and later an AI consultancy, Vingyani. Then he returned to academia as a Professor of Data Science at the Indian Institute of Science Education and Research, Bhopal. Currently, Parthiban is a Professor and Director at the Center for AI in Medicine, Vinayaka Missions Research Foundation, AV Medical College and Hospital, Puducherry, India

• Data Science & Analytics Technologies
• Generative AI Tools

Dr. Eric Stahlberg is the Executive Administrative Director, Institute for Data Science in Oncology, at MD Anderson Cancer Center. Previously he directed cancer data science initiatives at the Frederick National Laboratory, having led and launched several initiatives at the lab. He was instrumental in establishing the Frederick National Laboratory’s high-performance computing initiative and in assembling scientific teams across multiple, complex organizations to advance predictive oncology. Stahlberg first joined the Frederick National Laboratory in 2011 to form and direct the National Cancer Institute’s Center for Cancer Research Bioinformatics Core, which helped build intramural research collaborations between the national laboratory and the National Cancer Institute. Since then, Stahlberg has played a leadership role in many key partnerships, including a major collaboration between the National Cancer Institute and the Department of Energy. Under the Joint Design of Advanced Computing Solutions for Cancer (JDACS4C), the National Cancer Institute and Department of Energy are accelerating progress in precision oncology and computing. The collaboration is rooted in three major national initiatives; the Precision Medicine Initiative, the National Strategic Computing Initiative, and the Cancer Moonshot. He has helped lead initiatives to transform data management approaches at the lab as well as more recently leading program efforts exploring the application biomedical digital twins for cancer applications. Stahlberg has spearheaded the Frederick National Laboratory’s contributions to a number of JDACS4C projects, including ATOM and CANDLE. He helped launch the annual meeting series, Frontiers in Predictive Oncology and Computing, and co-organizes the annual Computational Approaches for Cancer and HPC Applications of Precision Medicine workshops. In 2017, he was recognized as one of FCW‘s Federal 100. Stahlberg holds a Ph.D. in computational chemistry from The Ohio State University.

• AI for Oncology, Precision Medicine & Health
• Data Science & Analytics Technologies

Rebecca Stevenson HSBC Rebecca (Becky) Stevenson is Head of Healthcare Investment Banking for the Americas at HSBC. Becky previously served as a Managing Director on the Biopharma Investment Banking team within the Healthcare Corporate & Investment Banking group at Wells Fargo where she advised, and executed on behalf of, biopharma companies’ long-term strategic financing, M&A, partnership and overall business development strategies.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Chris Stumpf is Director, Drug Discovery Informatics Solutions at Revvity Signals. Chris has over 20+ years of experience in the Analytical Instrumentation and Informatics industry spanning Pharmaceuticals & Life Sciences to Chemicals & Materials. He has a Ph.D. in Analytical Chemistry and Mass Spectrometry from Purdue University.

• Pharmaceutical R&D Informatics

Dr. Su is a postdoc fellow at Harvard Medical School and works with Prof. Marinka Zitnik. Her research interests include Biomedical Knowledge Graphs, LLM Agents, and their applications in Bioinformatics.

• Knowledge Graphs

No bio available.

• Bioinformatics

Kian Tan obtained his BS degree in 1999 from the University of Virginia and PhD degree in 2004 from the University of California-Berkeley under the joint supervision of Professors Robert Bergman and Jonathan Ellman. He continued his scientific development as an NIH postdoctoral fellow in the laboratories of Professor Eric Jacobsen at Harvard University from 2004-2006. After his post-doctoral studies, he initiated an independent academic career at Boston College where he investigated the use of reversible covalent bonding as a means of enhancing reactivity and selectivity for metal and non-metal catalysts. In 2012, he moved to the Novartis Institutes of Biomedical Research (NIBR) to lead the SynTech group. The group focuses on developing and implementing new methodology and technology to accelerate drug discovery through synthesis. Over the course of his career he has been the recipient of several honors and awards including Kavli Fellow (2012), NSF CAREER Award (2012), and Alfred P. Sloan Fellow (2011).

• AI for Drug Discovery & Development

Iman Tavassoly, MD, PhD, is a highly experienced physician-scientist specializing in computational biology and quantitative medicine. With over 14 years of experience in the field, he has gained a reputation for his ability to apply cutting-edge quantitative techniques and technologies to advance healthcare research. His expertise in AI-based precision medicine and systems pharmacology has been instrumental in developing innovative solutions to the most pressing challenges in modern medicine. Currently serving as Senior Director at C2i Genomics, Dr. Tavassoly continues to make significant contributions to the field and is widely respected as an expert in precision medicine.

• Generative AI Tools

Vas leads the customer team for Globus, an innovative software-as-a-service for research data management, developed and operated by the University of Chicago. He works with current and prospective users to grow adoption of the service and make it self-sustaining. Vas is also a lecturer in the Master's Program in Computer Science, where he teaches courses on Cloud Computing and Product Management. Vas has 30 years of experience in operational and consulting roles, spanning strategy, marketing, and technology. He has nurtured early-stage companies into successful businesses and consulted with companies on a wide range of strategic issues. Vas holds an MBA from the Ross School of Business at the University of Michigan, Ann Arbor, and a BS in Electrical Engineering from the University of the Witwatersrand in South Africa.

• Software Applications & Services

Laszlo Vasko’s career in leading technology-enabled innovation in drug development spans over twenty at Wyeth, Accenture, AstraZeneca, and now Janssen Pharmaceuticals. Throughout this career, Laszlo seized opportunities to engage drug development leaders in improving the delivery of new medicines in areas such as structured clinical trial design, AI-enabled regulatory knowledge mining, EHR for research, etc. He currently leads a team focused on supporting novel therapeutic and development modalities, such as CAR-T cell therapy development, EHR for sponsor research, digital health-enabled study delivery, and innovation pilots such as AI voice in clinical research. Laszlo has Master’s of Science degree, in Clinical Research Operations Management from Drexel University’s College of Medicine as well as Master’s of Science in Information Science from Penn State. He brings forth a blend of technical and functional expertise, combined with business change management skills. His passion outside of work is aviation: Laszlo is a private pilot flying both powered planes and gliders and is an active member of the Greater Boston Soaring Association.

• Digitalization of Clinical Development

Mariano Vázquez is co-founder, CTO / CSO of ELEM Biotech, and researcher at the Barcelona Supercomputing Center (BSC). ELEM, a spinoff company of the BSC, was born to speed up the technology transfer from BSC to the biomedical sector by creating a supercomputer-based and cloud-deployed platform to perform in-silico clinical trials on massive populations of Virtual Humans. Virtual Humans are "avatars", a combination of sophisticated mathematical and computational modelling and data designed to predict the outcome of different therapies. Powered by BSC, our team develops tools which allow us to study the cardiovascular and respiratory systems with customers in both the medical devices sector and the pharmaceutical industry. Infarction, ageing, damaged cardiac valves, arrhythmias, stent design, and respiratory drug delivery are among the topics where such a tool can become a decisive help.

• Data Science & Analytics Technologies

Dr. Jo Viney, Ph.D., is Cofounder, President and CEO of Seismic Therapeutic, the machine learning immunology company developing medicines for autoimmune disease. A seasoned biotech executive and entrepreneurial scientist, she has co-founded 3 biotech startup companies in MA - the first of which, Pandion Therapeutics, was acquired by Merck in 2021 for $1.85B. Prior to Pandion she held research leadership positions and contributed to the drug discovery pipelines at Biogen, Amgen, and Immunex. She is an experienced director on both private and public company boards. Jo is a big advocate for workplace inclusiveness and regularly volunteers her time with a number of organizations focused on increasing diversity.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Anna Marie Wagner’s career has spanned investing and operating roles in both hypergrowth and mature companies, focused on technology and the life sciences. She currently advises organizations across both the public and private sectors including DARPA and several private techbio innovators. Previously, Anna Marie was on the executive team at Ginkgo Bioworks (NYSE:DNA), where over the years she built and led numerous functions including finance, corporate development, and AI. Anna Marie led Ginkgo’s public offering in 2021, raising $1.6 billion in what still is the largest-ever go-public raise in biotech, and launched Ginkgo's AI efforts, including its marquee collaboration with Google. Previously, she was a technology investor at Bain Capital Private Equity where she focused on vertical software, marketplaces, and digital media businesses. Since 2023, she has also been serving as an Executive Fellow at Harvard Business School, where she co-teaches an elective course on failure (and loves the irony!). Anna Marie lives in Boston and her house is overrun with boys - in the form of a husband, two children, and two cats.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Michael Wan is a Research Scientist at the Institute for Experiential AI at Northeastern University, working out of Northeastern's Roux Institute campus in Portland, Maine. Michael's research is in machine learning and health. He develops deep learning and computer vision tools to advance health research, particularly in developmental health and biomedical imaging, in close collaboration with researchers in psychology and medicine.

• AI for Oncology, Precision Medicine & Health

Monica currently leads the Biology (including Biologics) Capabilities and Products in Takeda Scientific Informatics. She comes with multidiscipline education with PhD in Biochemistry and MSc in Software Engineering. She has 8+ years of experience in academic research and 15+ years of experience in Research Informatics in the biotechnology and pharmaceutical industries. She is good at strategic planning with proven successful track records of managing complicated global enterprise informatics projects. She has delivered many informatics projects/programs within time and budget for many departments (Global Biologics, Molecular Pathology, Protein Science, Biotherapeutics, Translational Medicine, and Legal IP, et al). She is technically and scientifically proficient in Bioinformatics, Cheminformatics, Functional Genomics, and Pharmacogenomics. Her team has designed and implemented many global enterprise informatics solutions to support biologics research, biomarker discovery, translational research, and personalized medicine. Her recent focus is concentrated on building a state-of-art Global Biologics Platform to support the global biologics R&D research in Oncology, GI, and CNS across Takeda.

• Digital Biopharma

Jenny Wei is the Head of R&D Informatics and Technology at Kite Pharma. She has over 23 years of experience in the pharmaceutical industry delivering innovative digital solutions and advanced analytics for small molecule, biologics, and cell therapy R&D, real-world evidence generation, process development, clinical manufacturing, and supply chain. Trained as a biologist and a computer scientist, she holds a master’s in Computer Science from Rutgers University and a Ph.D. in Pharmacology from the University of Washington.

• Generative AI
• Digital Biopharma

My background is in Computer Science, Math, and Molecular Biology. I work in the pharmaceutical industry, and my top research interests are: * GRAPH DATABASES / KNOWLEDGE REPRESENTATION: I'm the lead architect of the open-source project Brain Annex: Full Technology Stack on top of Neo4j Graph Databases (https://BrainAnnex.org). Example of use case: Multimedia Knowledge Management System * DYNAMICAL MODELING OF BIOLOGICAL SYSTEMS I lead an open-source project: https://life123.science * MACHINE LEARNING and NEUROCOMPUTING The cusp of theoretical neuroscience and "traditional" machine learning, especially different data domains, the integration of ML and genetic algorithms, heuristics for traversals of large search spaces in the absence of differentiable loss functions (especially to control dynamical systems such as those in Life123.science), self-evolving network topology, and General Artificial Intelligence. I've been doing research and development on a platform to integrate Tensorflow-based ML with pulse networks.

• Bioinformatics

Nick is a Data Architecture, Standards and Flow at Novartis Biomedical Research. Nick holds a Master's degree in Computer Science and has worked in various software and data engineering roles in pharma/biotech over the past 13+ years, including a brief tenure at Waters Corporation before joining Novartis in 2014. While at Novartis, Nick helped design and implement several information systems in the screening and imaging spaces, and served as technical lead for a suite of High Content Image Analysis systems where he had the chance to present his work at the main stage of AWS re:Invent 2018. His current focus is on the New Modalities space - rearchitecting the RNAi registration ecosystem and workflows to be fit for purpose now and in the years to come.

• Cloud for AI/ML & Modern Data Science

Blake joined NEA in 2014 and focuses on investments in digital health, healthcare services, and biopharmaceuticals. At NEA, Blake co-manages the firm’s digital health and healthcare services practice, across both venture and growth investing verticals. Additionally, Blake also co-manages the firm’s public biopharma investing practice and is also a member of the Asia investing team and is involved with the firm’s healthcare investments in the region. Prior to NEA, Blake was a member of the private equity group at Ares Management, focused on investments in healthcare. Blake’s prior work experience also includes investment banking at Moelis & Company, where he was focused on transactions in healthcare, as well as equity research at Barclays Capital. Blake graduated from The Wharton School at the University of Pennsylvania, with a B.S in Economics with concentrations in finance, real estate and management.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

Alexander Wyss is a data engineer and solution architect specializing in AI/ML applications for healthcare and pharma. Currently at Roche Pharma pRED, he develops data infrastructures and tooling for ML/AI products for research projects. His work focuses on leveraging cutting-edge technologies to address intricate challenges in the biotech sector, particularly in areas such as data management and HITL visual interactive tools.

• Data Management

Dr. Lina Yang is a senior scientist in Johnson & Johnson Innovative Medicine. With over a decade of expertise in basic research, clinical trials, and data management for new drug and cell therapy development from academic fields, she has committed to delivering cutting-edge data science solutions to advance therapy development and improve patient outcomes.

• Digital Biopharma

As co-founder of Blue and co-inventor of our core technology, Ajay directs scientific and experimental efforts at Blue. He has over 15 years of research experience in opioid medicinal chemistry and the neurobiology of pain. Ajay completed his doctoral studies in the lab of Dr. Philip Portoghese at the University of Minnesota. Ajay completed his postdoctoral training under renowned pain neurobiologist Clifford Woolf at Harvard Medical School. He has authored several papers published in high-impact, peer-reviewed journals in the CNS space, including several book chapters and invited reviews. He is also a recipient of the Bacaner Research Award from the Minnesota Medical Foundation.

• Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY

As part of pRED Data & Analytics I am working as a Data Engineer for oligonucleotide therapeutics at the RNAHub at Roche since 2023. Here, I am responsible for building the data infrastructure and culture around all oligonucleotide data from early discovery projects. I lead multiple initiatives and support colleagues with everything from analytics and ML to software development for business-critical tools and data products. Previously I have done a rotational Postdoc in Translational Medicine Data Science at Novartis Biomedical Research where I gained excellent understanding of pharmacokinetic, preclinical safety and early clinical trial data. I hold a PhD in Cheminformatics from the University of Bonn and a Diploma in Pharmacy (licensed pharmacist). I have 8 years of experience in data mining, machine learning, and analytics as well as 5 years of experience in wet lab, including molecular biology and analytical chemistry. I have contributed with over 15 scientific publications in all fields I have worked in so far. I am truly passionate to help discovering and developing novel drugs for patients around the world and have a particular interest in ophtalmology, neuroscience and infectious diseases.

• AI for Drug Discovery & Development

With 16+years of experience in the Roche Pharma R&D informatics, Shijun has developed a deep expertise in building end-to-end biological workflows with FAIR principles, establishing information and data models for the emerging areas, and facilitating the data integration, querying and visualization to accelerate the drug discovery. In the last five years, she managed and developed the D360 platform as the key portfolio dashboard to advance the data-driven decision-making in Roche Pharma Early Research and Development (pRED) organization, spanning cross-therapeutic areas and modalities (i.e. small molecule, oligo, biologics, cell and gene therapy).

• Digital Biopharma

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. Under his leadership, Insilico raised over $380 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 8 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule. Since 2015, he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. Since 2012, he published over 160 peer-reviewed research papers and 2 books. He founded and co-chairs the Annual Aging Research, Drug Discovery, and AI Forum (9th annual in 2022), the world's largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

• AI for Drug Discovery & Development
• Generative AI
• AI for Oncology, Precision Medicine & Health
• Bioinformatics
• Cloud for AI/ML & Modern Data Science
• Data Science & Analytics Technologies
• Pharmaceutical R&D Informatics
• Software Applications & Services
• Data Platforms & Storage Infrastructure
• Data Management
• Digitalization of Clinical Development

Marcin von Grotthuss, Director of Data Integration and Analytics with over 20 years of experience executing multidisciplinary translational projects, including 4 and 7 years of pioneering research in the analysis of clinical, molecular, and genomic data for drug discovery in rare and common diseases, and precision medicine applications at Takeda Pharmaceuticals and The Broad Institute, respectively. He earned a Ph.D. in Bioinformatics from Radboud University Nijmegen, Netherlands, and gained professional experience at the Sanford-Burnham Institute (La Jolla), University of Washington (Seattle), Harvard University, University of Cambridge (UK), University of California, Irvine, and Brigham and Women’s Hospital / Harvard Medical School.

• Cloud for AI/ML & Modern Data Science